

1 Neuromodulation with Ultrasound: Hypotheses on the Directionality of 2 Effects and a Community Resource

3 Hugo Caffaratti¹, Ben Slater², Nour Shaheen¹, Ariane Rhone¹, Ryan Calmus¹, Michael Kritikos¹,
4 Sukhbinder Kumar¹, Brian Dlouhy¹, Hiroyuki Oya¹, Tim Griffiths^{1,2}, Aaron D. Boes⁴, Nicholas Trapp⁴,
5 Marcus Kaiser⁵⁻⁶, Jérôme Sallet⁷⁻⁸, Matthew I. Banks⁹, Matthew A. Howard III¹, Mario Zanaty^{1*} &
6 Christopher I. Petkov^{1,2,3*}

7

8 * joint senior authors

9

10 **Affiliations:**

11 ¹ Department of Neurosurgery, University of Iowa, Iowa City, IA, USA

12 ² Biosciences Institute, Newcastle University Medical School, Newcastle upon Tyne, UK

13 ³ Iowa Neuroscience Institute, University of Iowa, Iowa City, IA, USA

14 ⁴ Department of Psychiatry, University of Iowa, Iowa City, IA, USA

15 ⁵ NIHR Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, UK

16 ⁶ Rui Jin Hospital, Shanghai Jiao Tong University, Shanghai, China.

17 ⁷ Stem Cell and Brain Research Institute, INSERM U1208, University of Lyon, Lyon, France

18 ⁸ Department of Experimental Psychology, University of Oxford, Oxford, UK

19 ⁹ Department of Anesthesiology, University of Wisconsin at Madison, WI, USA

20

21 * Correspondence: mario-zanaty@uiowa.edu, hugoandres-caffaratti@uiowa.edu, cipetkov@uiowa.edu

22

23 **ABSTRACT**

24 Low-intensity Transcranial Ultrasound Stimulation (TUS) is a promising non-invasive technique for deep-
25 brain stimulation and focal neuromodulation. Research with animal models and computational modelling
26 has raised the possibility that TUS can be biased towards enhancing or suppressing neural function. Here,
27 we first conduct a systematic review of human TUS studies for perturbing neural function and alleviating
28 brain disorders. We then collate a set of hypotheses on the directionality of TUS effects and conduct an
29 initial meta-analysis on the human TUS study reported outcomes to date ($n = 32$ studies, 37 experiments).
30 We find that parameters such as the duty cycle show some predictability regarding whether the targeted
31 area's function is likely to be enhanced or suppressed. Given that human TUS sample sizes are
32 exponentially increasing, we recognize that results can stabilize or change as further studies are reported.
33 Therefore, we conclude by establishing an Iowa-Newcastle (inTUS) resource for the systematic reporting
34 of TUS parameters and outcomes to support further hypothesis testing for greater precision in brain
35 stimulation and neuromodulation with TUS.

36

37

38 **Keywords:** Non-invasive brain stimulation, focal ultrasound stimulation, low intensity, neuromodulation,
39 excitation, inhibition, suppression, clinical application

40

41 **Highlights:**

- 42
- 43 • Systematic review of human TUS studies for enhancing or suppressing neural function
 - 44 • Collated set of hypotheses on using TUS to bias towards enhancement or suppression
 - 45 • Meta-analysis results identify parameters that may bias the directionality of effects
 - 46 • TUS resource established for systematic reporting of TUS parameters and outcomes

47 INTRODUCTION

48 In the last decade, low-intensity focused Transcranial Ultrasound Stimulation (TUS) has emerged as a
49 promising non-invasive brain stimulation technique for neuromodulation in research and clinical settings.
50 TUS uses sound waves—in the 100 to 1,000 kHz range—that pass through the skull to deliver focal acoustic
51 energy onto a targeted brain area. Compared to other more established non-invasive brain stimulation
52 techniques, such as Transcranial Magnetic Stimulation (TMS), transcranial Direct Current Stimulation
53 (tDCS) or transcranial Alternating Current Stimulation (tACS), TUS offers several advantages: i) focal
54 deep brain targeting (Fig. 1); ii) multi-target, including bi-hemispheric, stimulation capabilities; and, iii)
55 neuromodulatory effects that can last tens of milliseconds to hours after the sonication period has ended
56 (Blackmore et al., 2023; Deffieux et al., 2015; Deffieux et al., 2013; Legon et al., 2014; Mueller et al.,
57 2014). The neural effects of TUS depend on factors including the intensity and duration of the acoustic
58 wave. In this review, we primarily focus on *low-intensity* TUS as used for neuromodulation (typically <50
59 W/cm²) (Food & Drug Administration, 2019; Lee et al., 2021), with some consideration of *moderate-*
60 *intensity applications* (>190 W/cm²) used for perturbing the blood-brain barrier (Kim et al., 2021; Spivak
61 et al., 2022; T. Zhang et al., 2021) and *high-intensity focused ultrasound* (up to 10,000 W/cm²) used for
62 clinical thermal ablation in neurosurgery patients (Zhou, 2011). The duration of TUS effects is another
63 factor, with immediate effects during TUS stimulation referred to as “online” effects and those that can last
64 after TUS stimulation referred to as “offline” effects.

65 Ultrasound for clinical imaging or thermal ablation has a long history. However, low-intensity
66 ultrasound for neuromodulation remains a relatively nascent approach for non-invasive brain stimulation.
67 Therefore, much remains to be understood about the mechanisms of TUS neuromodulation. Yet,
68 considerable research progress has been made with TUS in humans, nonhuman animal models and with
69 computational modeling, narrowing the range of possible mechanistic hypotheses.

70 *Candidate mechanisms for TUS neuromodulation.* Low intensity TUS in animal models has been
71 shown to interact with neural tissue via mechanical effects. The sonication wave either directly changes the
72 permeability of ion channels within neuronal membranes, such as voltage-gated sodium, calcium and
73 potassium channels (e.g., K2P, TRP and Piezo1), or it temporarily mechanically alters the cell membrane
74 properties. Several mechanisms have been proposed including changes in membrane turgidity, in the
75 dynamics of lipid microdomains or in the formation of microbubbles within the lipid bilayer (Anishkin et
76 al., 2014; Babakhanian et al., 2018; Petersen et al., 2016; Suki et al., 2020; Tyler, 2011). TUS also impacts
77 on the coupling between neurons and glial cells (Oh et al., 2019). The combination of TUS mechanical
78 effects leads to an increase in action potentials by excitatory and inhibitory neurons (Tyler, 2011; Yoo et al.,
79 2022). TUS has been shown to be capable of inducing muscle contraction and limb or tail flicking when
80 rodent motor cortex is stimulated with low to moderate intensities (Kim et al., 2020; Lee et al., 2018; Tufail
81 et al., 2010). However similar motor responses have yet to be observed and reported in human and non-
82 human primates (Darmani et al., 2022).

83 At the lower intensities for neuromodulation, TUS can influence neural tissue without causing
84 substantial damage, heating or adverse effects, as reported in human and non-human primates (Gaur et al.,
85 2020; Spivak et al., 2021; Verhagen et al., 2019). However, care should be taken with more continuous
86 stimulation protocols where the continuity of stimulation (duty cycle; see Box 1) is high (Roumazeilles et
87 al., 2021; Verhagen et al., 2019). Overall, TUS does not appear to cause significant heating or cavitation to
88 brain tissue when the time averaged intensity (ISPTA, see Box 1) remains below 14 W/cm². Temperature
89 changes for low-intensity TUS are commonly <1°C (Baek et al., 2017; Yoo et al., 2011), and thermal effects
90 can alter cell membrane capacitance during “online” TUS. However, thermal effects are unlikely to play a
91 considerable role for longer-lasting “offline” TUS effects (Ozenne et al., 2020; Verhagen et al., 2019). The
92 mechanism of action for the longer-lasting offline effects is not yet well understood. Because these effects

93 last tens of minutes, or in some case hours, after the sonication period (Bault et al., 2023; Pasquinelli et al.,
94 2019), they likely engage neuroplasticity mechanisms, such as modulation of AMPA and NMDA
95 glutamatergic receptors and/or post-synaptic Ca^{2+} mediated changes to receptor properties. Interestingly,
96 TUS effects on neuronal NMDA receptors appears to be indirect via, for instance, TUS modulation of
97 astrocytes that can then influence neuronal plasticity (Blackmore et al., 2023). TUS pulsed at a theta (4-8
98 Hz) rhythm (theta-burst TUS; tb-TUS) is being studied for its capability to induce LTP-like plasticity (Oghli
99 et al 2023, Samuel et al. 2022, Samuel et al. 2023, Zeng et al. 2022), which we consider as part of ‘offline’
100 stimulation protocols in section II or this review paper. Of importance for future clinical applications, the
101 repeated use of TUS sessions does not appear to negatively impact on the integrity of brain tissue as assessed
102 by MRI (Munoz et al., 2022).

103 Directionality of TUS neuromodulation. There is substantial interest in understanding the
104 conditions under which TUS could be used to bias the directionality of neuromodulatory effects on the
105 targeted brain area and its network or on behavior (Blackmore et al., 2023; Mihran et al., 1990; Tsui et al.,
106 2005; Zhang et al., 2023). To describe the directionality of effects we use the terms enhancement versus
107 suppression throughout, reserving the terms excitation and inhibition for reports where it was possible to
108 directly record from identified excitatory and inhibitory neurons with animal models.

109 Recordings from identified excitatory and inhibitory neurons during TUS with animal models
110 provide clearer mechanistic insights because the neuronal recordings can also be combined with causal
111 manipulation, such as blocking specific ion channels. For instance, recent studies with murine models have
112 reported that short sonication durations (<1 sec) can lead to net excitation (attributed to more action
113 potentials for excitatory neurons during TUS), whereas longer sonication durations (> 1 sec) can lead to net
114 suppression (i.e., more strongly driving inhibitory neurons) (Mihran et al., 1990; Tsui et al., 2005). Other
115 TUS studies have suggested that higher sonication Pulse Repetition Frequencies (PRF >100 Hz) can lead
116 to net excitation (Manuel et al., 2020; Zhang et al., 2023).

117 The caveat is that many nonhuman animal studies are conducted under anesthesia, which can alter
118 the balance of excitatory-inhibitory neuronal activity. By comparison, although human TUS studies are
119 often conducted without anesthesia, access to single units (neurons) is only possible with specialist FDA or
120 ethical board approved electrodes for clinical monitoring in neurosurgery patients. There is currently a
121 paucity of direct neuronal recording studies in humans during TUS.

122 Nonetheless, similar challenges in identifying the directionality of effects on neurons and neuronal
123 networks have been a focus of research using other non-invasive brain stimulation approaches, including
124 TMS (Fitzgerald et al., 2006). TMS researchers now regularly apply higher duty cycles to tip the
125 directionality of TMS neuromodulatory effects on cortical areas towards net excitation (i.e., potentiation).
126 By contrast, low-duty cycle TMS pulses are associated with net inhibition (i.e., de-potentiation or
127 suppression) of muscle potentials or motor cortical responses (Solomon et al., 2024). Therefore, although
128 the effects of TMS and TUS on neurons and neural systems differ, there appears to be some correspondence
129 in the stimulation parameter space that may result in net excitation or suppression of function.

130 Research into TUS mechanisms and effects is both informing and being guided by computational
131 modeling, which allows the more thorough systematic exploration of TUS stimulation parameters in ways
132 difficult to achieve with empirical study alone. In a computational *Neuronal Intramembrane Cavitation*
133 *Excitation* (NICE) model developed to study activation and suppression effects on modeled excitatory and
134 inhibitory neuronal populations, TUS effects were simulated as intramembrane cavitation causing changes
135 in ion channel conductivity (Plaksin et al., 2016). The NICE model explored a broad set of TUS parameters,
136 including TUS intensity and the continuity of stimulation (duty cycle). Box 1 summarizes the common TUS
137 parameters and their measuring units. Key parameters are the average acoustic intensity (intensity spatial

138 peak pulse average, ISPPA), temporally averaged intensity (ISPTA), sonication duration (SD), duty cycle
139 (DC), pulse repetition frequency (PRF), thermal index (TI) and mechanical index (MI). Box 2 shows
140 guidelines on the ultrasound parameter limits that human low-intensity TUS studies typically follow. The
141 NICE model was initially evaluated with a more limited set of the then available data from human and
142 nonhuman animal studies, and the model showed a high level of predictability. For instance, increases in
143 intensity (ISPPA, Box 1) and duty cycle can tip the balance from suppression to activation in the modelled
144 populations of excitatory and inhibitory neurons (Plaksin et al., 2016). Several reviews have now conducted
145 similar case-by-case or ad-hoc comparisons of TUS parameters with the NICE model predictions, with
146 mixed support for or against the NICE model (Ai et al., 2018; Dell'Italia et al., 2022; Forster et al., 2023b;
147 Zhang et al., 2023). In Box 3, we collate a set of net enhancement versus suppression hypotheses linked to
148 TUS parameters that may be able to bias the directionality of effects.

149 The uncertainty about the extent to which TUS can be used to enhance or suppress neurobiological
150 function limits its research potential (Chen et al., 1997; Fitzgerald et al., 2006). Rather than exploring the
151 TUS parameter space, many researchers opt to emulate the TUS parameters of prior studies reporting
152 specific positive findings, limiting the necessary exploration of the entire parameter space for a nascent
153 field. We recognize the complexity of neural circuits and systems and the limitations in aiming to evaluate
154 predictions with a relative paucity of data in humans. However, we also recognize that stepwise progress
155 and evaluation are needed as sign-posts in this research endeavor, not unique to TUS or other brain
156 perturbation approaches with longer histories of use (e.g., invasive deep-brain electrical stimulation, TMS,
157 tACS, tDCS; Fig. 1) (Derosiere et al., 2020; Klink et al., 2021). Therefore, since there are now over 30
158 human TUS studies (by January 1st, 2024; Figure 3), to us the time seems ripe for a research sign-post and
159 an open resource that can accommodate growth in the field. For instance, there are now a range of reported
160 behavioral and neurobiological outcomes with human TUS, ranging from eliciting somatosensory
161 sensations with TUS applied to the somatosensory cortex, the enhancement or suppression of the threshold
162 for motor-evoked potentials (MEPs) with TUS applied to motor cortex (including in combination with
163 TMS), the perception of visual phosphenes or modulation of visual motion perception from TUS applied
164 to the visual cortex, and mood improvement induced by TUS to the prefrontal cortex (these and others are
165 summarized in Tables 1-3). With these human low-intensity TUS data accumulating, a more extensive
166 review and meta-analysis than previously possible can now be conducted, which will be a step towards the
167 next evaluation period when the samples sizes further grow.

168 Our key objectives with this review are twofold. In the first part, we summarize the current state of
169 the literature on human TUS applications for perturbing the brain and as a possible treatment of neurological
170 and psychiatric disorders. This literature review identifies epistemic gaps in our understanding of how TUS
171 could be better applied to patients and whether TUS can be better used to enhance or suppress function. In
172 the second part, we evaluate the collated set of net enhancement versus suppression hypotheses (Box 3) and
173 conduct an initial meta-analysis of the available human low-intensity TUS reports. We conclude by
174 establishing an Iowa-Newcastle (inTUS) resource and tools for using TUS, to encourage TUS researchers
175 to more systematically explore and report on the broader TUS parameter space and outcomes. These are in
176 line with the International Transcranial Ultrasonic Stimulation Safety and Standards (ITRUSST)
177 consortium that has proposed standards to enable comparison and reproducibility across studies (Martin et
178 al., 2024).

179 **Part I. TUS applications review**

180 Compared to pharmaceutical drugs that can affect many parts of the brain and body, TUS allows the
181 stimulation of specific targets within the brain with relatively high spatial precision. Here, we review
182 potential applications for low-intensity TUS that are currently investigational or could be based on related
183 developments using other approaches (e.g., TMS). We also, albeit more selectively, consider moderate-

184 intensity applications for Blood Brain Barrier (BBB) perturbation and high-intensity TUS for clinical
185 thermal ablation. While the primary goal of BBB opening is to regionally increase the permeability of BBB
186 to enhance the efficacy of brain drug delivery, BBB opening alone could induce neuromodulatory effects
187 (Chu et al., 2015).

188 **Ia. Low-intensity TUS applications**

189 **Motor and somatosensory system mapping.** Intraoperative clinical motor and somatosensory cortical
190 mapping is important for planning neurosurgical treatment. TMS over the motor cortex is regularly used to
191 induce muscle contractions and limb movements. The effect of TMS on the amplitude of muscle-evoked
192 potentials is an accepted measure of motor cortical enhancement (increased motor-cortical evoked EEG
193 potentials) or suppression (decreased MEPs) (Fitzgerald et al., 2006). In preclinical research, low-intensity
194 (or moderate-intensity) TUS focused on motor cortex in rodents can induce muscle contractions (King et
195 al., 2014; Tufail et al., 2010; Yoo et al., 2011; Younan et al., 2013), including limb, tail, whisker or eye
196 muscle contraction (King et al., 2014). TUS in humans targeting the motor cortex has been reported to
197 either enhance or suppress MEPs (Table 1) (Gibson et al., 2018; Lee et al., 2016a; Legon, Bansal, et al.,
198 2018; Samuel et al., 2022; Xia et al., 2021; Zeng et al., 2022; Y. Zhang et al., 2021). Stimulation of the
199 primary motor cortex with TUS has been found to decrease reaction times in a stimulus-response task,
200 interpreted as enhanced motor performance (Fomenko et al., 2020; Legon, Bansal, et al., 2018; Zhang et
201 al., 2022; Y. Zhang et al., 2021).

202 For mapping of human somatosensory cortex, TUS has been reported to either enhance or suppress
203 somatosensory evoked potentials (SEPs) recorded with EEG, and TUS can elicit a range of somatosensory
204 perceptions, such as tactile sensations in the hand contralateral to the stimulated somatosensory cortex (Lee
205 et al., 2015; Legon et al., 2014). Legon *et al.* demonstrated impaired performance in a tactile spatial
206 discrimination task from TUS stimulation of the ventro-posterior lateral nucleus of the thalamus (Legon,
207 Ai, et al., 2018). This was reflected in the disruption of the corresponding SEP component (Legon, Ai, et
208 al., 2018). Dallapiazza *et al.* (Dallapiazza et al., 2017) targeting the swine sensory thalamus. These pre-
209 clinical studies with animal models and humans demonstrate the feasibility of using TUS to modulate the
210 somatosensory system safely and to map superficial and deep brain structures noninvasively in patients
211 using TUS. For clinical motor or somatosensory cortical mapping, TUS would need to be used to induce
212 motor behavior or somatosensory percepts by stimulating motor/somatosensory sites, or to suppress
213 ongoing motor functions (hand squeeze, arm drop).

214 **Speech and language mapping.** Intra-operative brain mapping using electrical stimulation is used by
215 neurosurgeons to identify brain areas crucial for speech and language (Benzagmout et al., 2007; Chang et
216 al., 2015; Duffau, 2010; Mandonnet et al., 2017; Mathias et al., 2016). The gold-standard approach
217 identifies speech and language areas using electrical stimulation to elicit speech arrest, naming or other
218 language difficulties (Duffau, 2010; Mathias et al., 2016). However, because of the limited time in the
219 operating room for patient brain mapping, there is considerable interest in developing pre-operative non-
220 invasive brain stimulation (NIBS) approaches for speech and language brain mapping. For instance, TMS,
221 when used with MRI-based neuro-navigation to target neocortical speech and language regions, can lead to
222 speech arrest or anomia, which generally corresponds to the locale of intra-operative mapping using
223 electrical stimulation (Tarapore et al., 2013). Furthermore, TMS is often integrated with adjunctive
224 methodologies such as electroencephalography (EEG), functional magnetic resonance imaging (fMRI), or
225 diffusion tensor imaging (DTI) to bolster the precision and specificity of brain-behavioral mapping. To date
226 there do not appear to be TUS studies focused on speech and language mapping, defining a clear research
227 need. For this clinical application, TUS would need to temporarily suppress brain areas important for speech
228 production and language function, analogous to the current use of electrical stimulation for intra-operative
229 mapping of neocortical areas involved in these processes.

230 **Mood disorders.** TUS has been explored as a possible treatment for psychiatric mood disorders. In a study
231 from 2013, in humans with chronic pain, TUS administered to the posterior frontal cortex contralateral to
232 the source of pain elicited a significant mood enhancement after 40 minutes (Hameroff et al., 2013).
233 Sanguinetti *et al.* reported that TUS targeting the right ventrolateral prefrontal cortex led to reports of
234 improved mood in healthy individuals after TUS (Sanguinetti et al., 2020). In a double-blind pilot study,
235 Reznik and colleagues applied TUS to the right fronto-temporal cortex of depressed patients, resulting in
236 mood improvement (Reznik et al., 2020; Shimokawa et al., 2022). Forster *et al.* used TUS to indirectly
237 manipulate cingulate cortex activity in a learned helplessness task, demonstrating the potential to affect the
238 response to acute stressors that can induce symptoms of depression (Forster et al., 2023). Further pre-
239 clinical and clinical trial studies would be necessary to evaluate TUS efficacy in alleviating or even
240 alleviating mood disorder symptoms. With such applications, TUS could be used to target highly-
241 interconnected brain network hubs associated with depression risk or resilience to modulate function (Trapp
242 et al., 2023). The ‘dose’ and longevity of TUS effects would need to be systematically explored.

243 **Schizophrenia.** Early pilot results for patients suffering from psychosis are now available. In a double-
244 blind, randomized, sham-controlled study, 15 sessions of TUS over the left dorsolateral prefrontal cortex
245 (DLPFC) could alleviate negative symptoms in schizophrenia patients and enhance cognitive performance
246 in a continuous performance test (Zhai et al., 2023). TUS was well tolerated with patients in the active
247 group not reporting more adverse effects than patients in the sham group. The use of TUS seems particularly
248 promising due to the involvement of deep-brain structures, such as the thalamus in this condition
249 (Mukherjee & Halassa, 2024). For TUS application to schizophrenia, TUS could be used to suppress the
250 function of areas reducing the positive or negative symptoms associated with schizophrenia.

251 **Disorders of Consciousness.** Low-intensity TUS has shown the capability to hasten the recovery of
252 behavioral responsiveness in patients with disorders of consciousness (Lee et al., 2016a). Monti and
253 colleagues documented a case where low-intensity TUS aimed at the thalamus was associated with the
254 emergence from a minimally conscious state in patients experiencing disorders of consciousness following
255 severe brain injury (Monti et al., 2016). For this clinical application, TUS would need to enhance the
256 function of thalamic nuclei and interconnectivity with other brain areas, such as the centro-median-
257 perifascicular nuclei of the thalamus and the mesencephalic reticular formation (Chudy et al., 2023).
258 However, a more permanent approach, such as electrical deep brain stimulation (DBS), may be required in
259 some patients or a combination of TUS ‘mapping’ followed by DBS.

260 **Alzheimer’s disease.** Cognitive decline associated with dementia would benefit from approaches that can
261 enhance cognitive function. In a study with 11 Alzheimer’s disease (AD) patients using transcranial pulse
262 stimulation (TPS; typically shorter pulses of low-intensity ultrasound stimulation over a longer period of
263 time) targeting the hippocampus, the authors reported that 63% of patients improved on one or more
264 cognitive assessments (Nicodemus et al., 2019). In another study involving 35 AD patients, shock waves
265 were applied to the dorsolateral prefrontal cortex (Beisteiner et al., 2020). The patients’ neuropsychological
266 scores significantly improved after TPS, and these improvements were reported to have persisted for up to
267 three months. Overall, these results demonstrate not only the capability of TUS for pre-operative cognitive
268 mapping but also the potential of TPS to be further researched to enhance cognitive function.

269 **Parkinson’s disease.** In a study by Nicodemus *et al.* involving 11 patients undergoing TUS application for
270 Parkinson’s Disease (PD) targeting the substantia nigra, it was reported that 87% of the patients had either
271 stable or improved fine motor scores and 88% had stable or improved gross motor scores (Nicodemus et
272 al., 2019). Samuel *et al.* used a technique called accelerated theta-burst TUS targeting the primary motor
273 cortex in 10 PD patients, studying its impact on neurophysiological and clinical outcomes (Samuel et al.,
274 2023). Their patients received both active and sham TUS conditions, and the authors measured TMS-
275 elicited motor-evoked potentials (MEPs) before and after treatment. The study found a significant increase

276 in TMS induced MEP amplitudes following TUS but not sham treatment. For non-invasive brain
277 stimulation clinical applications related to PD, TUS of the subthalamic nucleus would need to suppress its
278 function in a lasting way and with the precision to target the motor segment of the nucleus, rather than its
279 limbic or sensory segments.

280 **Epilepsy.** TUS application to an epileptogenic site has the potential to modulate seizure frequency. To
281 evaluate these possibilities, Lee et al. applied low-intensity TUS to individuals dealing with drug-refractory
282 epilepsy undergoing intracranial electrode monitoring with stereo-electroencephalography (SEEG) (Lee et
283 al., 2022). Two of the six patients studied showed a decrease in seizure occurrences, while one experienced
284 an increase. The TUS effects reported were close to electrode contacts positioned close to the subsequent
285 neurosurgical treatment site for epilepsy. Across all frequency bands in the local-field potential recorded
286 from the SEEG electrodes, there was a notable decrease in spectral power for all six patients following
287 TUS. However, there was no clear relationship between these immediate effects on interictal epileptiform
288 discharges and alterations in seizure frequency (Lee et al., 2022). Another study introduced a device for
289 delivering pulsed low-intensity TUS to the hippocampus in humans, with no reported adverse events after
290 multiple sessions (Brinker et al., 2020). A recently published pilot study by Bublick et al. described the
291 application of serial TUS in patients with mesial temporal lobe epilepsy. TUS was delivered in 6 sessions
292 over 3 weeks. No adverse events or side effects were reported. Early results were promising with significant
293 seizure reduction in 5 out of 6 patients, observed up to 6 months after TUS application (Bublick et al.,
294 2024). For epilepsy treatment TUS should aim to reduce the probability of seizures, but for clinical mapping
295 of epileptogenic sites TUS eliciting epileptiform activity could be a useful clinical mapping tool during
296 epilepsy monitoring procedures.

297 Sudden unexpected death in epilepsy. Sudden unexpected death in epilepsy (SUDEP) refers to the
298 sudden unexpected death of a person with epilepsy that cannot be explained by trauma, drowning, or status
299 epilepticus. On post-mortem examination, no structural or toxicological cause of death can be ascertained.
300 SUDEP is one of the leading causes of premature deaths in epilepsy, accounting for more than a 20-fold
301 increase in the risk of sudden death in epileptic patients compared with the general population (Ficker et
302 al., 1998; Kløvgaard et al., 2022). Among all neurological conditions, it ranks second after stroke in terms
303 of years of potential life lost (Thurman et al., 2014). Rare cases of SUDEP of patients in epilepsy monitoring
304 units have shown that cessation of breathing (apnea) following seizures precedes terminal asystole and
305 death (Bateman et al., 2008; Nashef & Brown, 1996; Ryvlin et al., 2013). Animal models (Johnston et al.,
306 1995) confirm a primary role of respiratory dysfunction in SUDEP. In the human patient work by Dlouhy
307 and colleagues (Dlouhy et al., 2015; Harmata et al., 2023; Rhone et al., 2020), it was shown that when a
308 circumscribed site in the amygdala, referred to as the Amygdala Inhibition of Respiration (AIR) site, is
309 affected either by the spread of seizure or by electrical stimulation, apnea occurs without the patient feeling
310 any air hunger or alarm (Lacuey et al., 2017; Nobis et al., 2019). In a subsequent study by Harmata et al.,
311 2023, electrical stimulation or stimulation evoked seizure within a focal region of the AIR site evoked apnea
312 that persisted well beyond the end of stimulation or seizure. Because this site in the amygdala caused
313 persistent inhibition of respiration, the authors referred to this site as the pAIR site. The AIR site, therefore,
314 is posited as a brain region that mediates seizure-induced inhibition of breathing which can persist for
315 minutes and may lead to SUDEP.

316 Localization and characterization of the AIR site and pAIR site have so far been done using
317 electrical stimulation in patients who have electrodes implanted for potential surgical remediation of
318 epilepsy. This puts a severe constraint in that only a limited population of individuals with epilepsy who
319 are candidates for electrode implantation have contributed to the characterization of the sites. Extension to
320 a larger population of epileptic patients without amygdala implantation and non-epileptic patient controls
321 require the use of non-invasive methods. Given the deep subcortical location of the AIR and pAIR sites,
322 approaches such as TMS are less suitable for this purpose. Because TUS has the capability to target deep

323 areas with higher spatial resolution, it can be used to target not only the AIR sites in the amygdala and the
324 respiratory network underlying SUDEP. TUS would likely need to suppress amygdala function to prevent
325 apnea. Although there is a pressing research need, we could not find studies, in epilepsy patients or other
326 cohorts, reporting TUS effects either that evoked apnea or stimulated breathing. Rather than controlling
327 SUDEP risk during epileptic seizures, if TUS cannot be implemented continuously, its utility may be better
328 suited to identify people at very high risk based on seizure-associated apnea, following by using TUS to
329 attempt to modulate the AIR site to confirm its location for subsequent neurosurgical ablation to reduce
330 epilepsy patient SUDEP risk.

331 **Stroke and neuroprotection in brain injury.** Low-intensity TUS has been studied for its potential
332 neuroprotective benefits following brain injury (Bretszajn & Gedroyc, 2018; Schellinger et al., 2015). Brief
333 application of TUS appears to boost the density of brain-derived neurotrophic factor (BDNF) in the
334 hippocampus, suggesting that TUS may enhance neuroplasticity (Tufail et al., 2010). Furthermore, TUS
335 has the ability to elevate BDNF and vascular endothelial growth factor (VEGF) expression in astrocytes
336 while also appearing to prevent cell apoptosis (Su et al., 2017; Yang et al., 2015). Chen *et al.* treated mice
337 with TUS before inducing cerebral ischemia and reported increased BDNF expression, improved
338 neurological function and decreased neuronal cell apoptosis (Chen et al., 2018).

339 In a randomized controlled trial, Wang *et al.* investigated the effects of TUS combined with
340 cognitive rehabilitation on post-stroke cognitive impairment (Wang et al., 2022). The research involved 60
341 patients randomly divided into observation and control groups, with the observation group receiving both
342 TUS intervention and conventional cognitive rehabilitation. The observation group exhibited improvement
343 in a range of cognitive measures compared to the control group, which only received conventional cognitive
344 rehabilitation. Other authors have studied how low-intensity TUS can affect outcomes from recurrent stroke
345 in mice. Wu *et al.* reported that continuous TUS treatment before secondary stroke lessened neuronal
346 damage and increased BDNF expression (Wu et al., 2019). This type of work suggests that TUS could be a
347 potential preventive therapy for recurrent stroke, presuming it can be delivered continuously as needed. In
348 another study, TUS was reported to enhance neurological recovery post-stroke in mice by promoting angio-
349 neurogenesis (Ichijo et al., 2021). In related studies of TUS applied to the body rather than the brain, TUS
350 was reported to be capable of boosting vasculogenesis by facilitating the formation of vascular networks in
351 human umbilical vein endothelial-cell cultures (Imashiro et al., 2021). Hanawa *et al.* introduced TUS as a
352 potential non-invasive therapy for ischemic heart disease. They found that TUS treatment significantly
353 improved left ventricular function and increased capillary density in a porcine model of chronic myocardial
354 ischemia (Hanawa et al., 2014), highlighting the research need to evaluate whether similar effects can be
355 replicated in the brain.

356 TUS has also been explored as a non-invasive thrombectomy tool to enhance thrombolysis with
357 tissue plasminogen activator in acute stroke (Schellinger et al., 2015). For stroke thrombectomy, TUS would
358 act to break up thrombocytes with or without a tissue plasminogen activator. An earlier study, by Liu *et al.*,
359 indicated that administering TUS soon after a stroke could yield neuroprotective effects (Liu et al., 2019).
360 Thus, there has been interest in evaluating whether initiating TUS promptly post-stroke could effectively
361 enhance cerebral blood flow, revive local circulation, save the ischemic penumbra, and minimize brain
362 tissue harm. A Phase II clinical trial showed low-intensity TUS could enhance the thrombolytic efficacy of
363 tissue plasminogen activator. However, TUS appears to have also led to a higher incidence of a cerebral
364 hemorrhage in patients concurrently treated with intravenous tPA (Daffertshofer et al., 2005). Another
365 Phase II clinical trial conducted across four centers, reported that in individuals with acute ischemic stroke,
366 TUS amplified tPA-induced arterial recanalization, showing only a non-significant trend toward an elevated
367 rate of stroke rehabilitation when compared to the control group. The occurrence of symptomatic

368 intracerebral hemorrhage was comparable between the active and control groups (Katsanos et al., 2020;
369 Schellinger et al., 2015).

370 **Hypertension and cardiovascular system effects.** As a promising noninvasive therapy for drug-refractory
371 hypertensive patients, Li and colleagues demonstrated the antihypertensive effects and protective impact
372 on organ damage by using low-intensity TUS stimulation in spontaneously hypertensive rats (Li et al.,
373 2023). The experiment involved daily 20-minute TUS stimulation sessions targeting the ventrolateral
374 periaqueductal gray in the rats for two months. Their results showed a significant reduction in systolic blood
375 pressure, reversal of left ventricular hypertrophy, and improved heart and kidney function. The sustained
376 antihypertensive effect may be attributed to the activation of antihypertensive neural pathways and the
377 inhibition of the renin-angiotensin system. Ji and colleagues explored the feasibility of using low-intensity
378 TUS to modulate blood pressure in rabbits (Ji et al., 2020). The study used a TUS system to stimulate the
379 left vagus nerve in rabbits while recording blood pressure in the right common carotid artery. Different
380 TUS intensities were tested, showing a decrease in systolic and diastolic blood pressure, mean arterial
381 pressure and heart rate (Ji et al., 2020). The higher the TUS intensity, the more significant the blood pressure
382 reduction. These pre-clinical studies in animal models highlight the possibility of non-invasive, non-drug
383 management of hypertension using TUS, opening avenues for treating clinical hypertension non-invasively.
384 For this clinical application, TUS would need to suppress sympathetic nodes (e.g., rostral ventro-lateral
385 medulla) or enhance parasympathetic nodes (e.g., medial prefrontal cortex) in the central autonomic
386 network (Macefield & Henderson, 2020; Shoemaker, 2022).

387 **Ib. Moderate intensity TUS applications**

388 **Enhancing pharmacological- and immuno-therapy through the blood-brain barrier.** A significant
389 challenge in drug- or immune-therapy is the limited effectiveness of drugs and vectors that do not easily
390 traverse the blood-brain barrier (BBB) (Hynynen et al., 2006; Mehta et al., 2021), an issue that has been
391 explored in the context of using antibodies to amyloid β to treat Alzheimer's disease. TUS has the ability
392 to temporarily open the BBB, facilitating the entry of such vectors into the brain from the blood stream.
393 Systemic injection of microbubbles when combined with TUS temporarily opens the BBB, with BBB
394 integrity restored within 4–6 hours (Hynynen et al., 2006; Mehta et al., 2021). Lipsman and colleagues
395 conducted a phase I safety trial, using TUS to safely and reversibly open the BBB in five patients diagnosed
396 with early to moderate Alzheimer's disease (Lipsman et al., 2018). They achieved predictable BBB opening
397 at approximately 50% of the power at which cavitation was observed during a test using the NeuroBlate
398 system. Right after the ultrasound treatment, a distinct rectangular-shaped enhancement was visible in the
399 targeted brain region on T1-weighted gadolinium MR images. This enhancement was resolved within 24
400 hours after the procedure, suggestive of successful closure of the BBB. The moderate intensity TUS did not
401 lead to any significant clinical or radiographic adverse events, nor a noticeable decline in cognitive scores
402 at the three-month follow-up when compared to baseline. Importantly, no serious adverse events, such as
403 hemorrhages, swelling, or neurological deficits were reported either on the day of the procedure or during
404 the follow-up study period. Rezaei *et al.* employed TUS to breach the BBB in a study involving six AD
405 patients (Rezaei et al., 2020). Post-treatment contrast-enhanced MRI scans displayed rapid and significant
406 enhancement in the hippocampus, which subsequently resolved. Throughout the several TUS treatments,
407 no adverse effects were observed, and there was no cognitive or neurological function decline. In a study
408 by Jeong *et al.* involving four AD patients, moderate-intensity TUS of the hippocampus did not exhibit
409 evidence of actively opening the BBB, as observed in T1 dynamic contrast-enhanced MRI (Jeong et al.,
410 2021; Jeong et al., 2022). However, the authors found that the regional cerebral metabolic rate of glucose
411 (rCMRglu) in the superior frontal gyrus and middle cingulate gyrus significantly increased following TUS
412 treatment. The patients also demonstrated mild improvement in measures of cognitive function, including
413 memory, after TUS. Although BBB opening could lead to neuromodulatory effects, its effects at the network
414 level are distinct from those achieved with TUS (Liu et al., 2023).

415 **Ic. High-intensity ultrasound for thermal ablation**

416 **Parkinson's disease.** Moser et al. introduced high-intensity MR-guided TUS for thermal ablation as a
417 potential treatment option for Parkinson's disease, employing it to target and ablate the connections between
418 the thalamus and globus pallidus (Moser et al., 2013). Their approach improved the patients' Unified
419 Parkinson's Disease Rating Scale (UPDRS) score by 57%. This therapeutic impact of high-intensity
420 ultrasound was replicated by Magara *et al.* in 2014, who used MR-guided TUS to thermally ablate the
421 unilateral pallidothalamic tract in PD patients, resulting in significant improvement in the UPDRS score
422 three months post-surgery (Magara et al., 2014).

423 **Essential tremor.** TUS at higher intensities that cause tissue ablation has FDA-approved application for
424 essential tremor following large, randomized clinical trials (Choi & Kim, 2019; Krishna et al., 2018).
425 Precision TUS thermal ablation of subthalamic nuclei is increasingly considered as an alternative to deep
426 brain stimulation for select patients (Rohani & Fasano, 2017). MR-guided focused ultrasound is being
427 employed in treating essential tremor (ET) with the thalamic ViM nucleus as the primary target (Abe et al.,
428 2020; W. S. Chang et al., 2015; Elias et al., 2013; Elias et al., 2016; Lipsman et al., 2013; Meng et al.,
429 2018). This non-invasive thalamotomy technique has demonstrated therapeutic benefits for essential tremor
430 patients and received FDA approval for unilateral treatment (Elias et al., 2016). The reported side effects
431 of thermal ablation with high-intensity TUS include early symptoms of dizziness, nausea/vomiting,
432 headache, skull overheating, flushing, and late symptoms such as ataxia and paresthesias (Abe et al., 2020;
433 W. S. Chang et al., 2015; Elias et al., 2013; Elias et al., 2016; Lipsman et al., 2013; Meng et al., 2018).
434 Further research is necessary to better establish TUS approaches for thermal ablation in ET patient therapy.

435 **Epilepsy.** In a recent case report, MR-guided high-intensity TUS was found to be effective in a patient with
436 medically intractable epilepsy, resulting in 12 months of seizure freedom (Abe et al., 2020). For a more
437 extensive review of TUS for thermal ablation in epilepsy patients, see (Cornelssen et al., 2023).

438

439 **Part II. Net enhancement and suppression hypotheses and meta-analysis**

440 In this section, we consider the rationale for the hypotheses regarding the directionality of TUS effects (Box
441 3), overview the approach for the meta-analysis and discuss the initial results obtained. We conclude by
442 establishing an Iowa-Newcastle (inTUS) community resource for TUS parameter and outcome reporting to
443 encourage further hypothesis development and testing.

444 **Net enhancement and suppression hypotheses.** The hypotheses summarized in Box 3 are based on TUS
445 parameters that have been highlighted by the TUS literature may be able to bias effects towards
446 enhancement or suppression. These hypotheses were generated from the NICE model (Plaksin et al., 2016;
447 Plaksin et al., 2014) and preclinical studies with animal model of TUS effects reported to result in greater
448 excitation or inhibition using direct recordings of excitatory and inhibitory neurons. The NICE model
449 hypothesized that key parameters associated with net activation or suppression (using the authors'
450 terminology) are sonication intensity in the target brain area (ISSPA in brain) and the continuity of
451 stimulation (duty cycle, DC). The NICE model predictions are shown in Figure 4 with a light blue line
452 defining the border between enhancement (higher DC and intensity) and suppression (lower DC and
453 intensity) resulting from the NICE modeling. In this regard ISPTA, which mathematically integrates ISSPA
454 by the sonication DC, can be considered the TUS "dose". Other parameters of interest are the length of the

455 sonication pulse (Sonication Duration, SD) with shorter SDs (<500 ms) tending to elicit more action
456 potentials from excitatory neurons, and longer SDs (>500 ms) tending to bias towards suppression via
457 greater excitation of *inhibitory* neurons (Mihran et al., 1990; Tsui et al., 2005). Other studies have suggested
458 that pulse-repetition frequency (PRF), the frequency with which the ultrasound pulse is turned on/off can
459 bias towards greater net excitation or suppression (Kim et al., 2023; Yu et al., 2020).

460 **Segregating online versus longer lasting ‘offline’ effects.** Studies of online or offline effects tend to use
461 different TUS parameters (compare Tables 1 and 2). Offline effects of TUS stimulation are induced for
462 longer time periods of time (seconds or minutes) by keeping the intensity of stimulation within FDA
463 guidelines. Therefore, for offline studies, DC and ISPTA values are often kept low (Box 2). For this reason,
464 we summarize the online and offline studies in separate tables (Tables 1-2) and include this distinction as
465 a factor in the meta-analyses.

466 **Meta-analysis inclusion criteria and analysis approach.**

467 This review follows the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)
468 guidelines. We searched PubMed/MEDLINE (www.ncbi.nlm.nih.gov/pubmed), Web of Science
469 (<https://www.webofscience.com>), and Scopus (<https://www.scopus.com>) databases.

470 We searched these databases for studies published through 1st January 2024 by employing the
471 combination of the following keywords and terms: ‘human’, ‘ultrasound’, ‘focused’, ‘low-intensity’,
472 ‘stimulation’, ‘transcranial’, ‘neuromodulation’, ‘TUS’, ‘FUN’, ‘LIFUS’ ‘clinical’, ‘treatment’. We
473 searched only for articles published in English. The included studies encompassing both healthy individuals
474 and patients with various medical conditions. Four authors (HC, NS, CP and MZ) searched for and curated
475 the included studies to ensure that the survey was as comprehensive as possible. The PRISMA
476 recommended search process is shown in Fig. 3. Eligibility criteria for the meta-analysis focused on human
477 studies involving low-intensity TUS for brain stimulation or neuromodulation applied. Of this total, only
478 32 were included in the meta-analysis. For the meta-analysis we only included studies that either reported
479 a basic set of TUS stimulation parameters or those sufficient for estimating the required parameters
480 necessary for the meta-analysis. For this reason, we had to exclude 4 diagnostic ultrasound studies (Gibson
481 et al., 2018; Guerra et al., 2021; Hameroff et al., 2013; Schimek et al., 2020), which did not report the
482 parameters we needed for the meta-analysis. These studies used an ultrasound imaging system, and
483 therefore could not carefully control the continuity or intensity of the ultrasound system. We excluded
484 studies with moderate-intensity or high-intensity ultrasound used for, respectively, BBB perturbation or
485 thermal ablation.

486 The reported studies’ TUS parameters and reported effects were used to populate the data tables
487 (Table 1 for online studies and Table 2 for offline studies). Most parameters required for the analysis could
488 be found in the reported studies, or could be calculated from the parameters given. If a given study
489 conducted multiple complete experiments, the sample sizes reflect the overall number of experiments rather
490 than the number of studies/papers, and if separate experiments tested different values of a given parameter
491 with the same result or reported directionality, the experiment eliciting the strongest effect was input into
492 the meta-analysis. A number of experiments (n = 14 out of 37), although reporting ISPPA values in water,
493 did not report ISSPA values in the brain required for our analyses, a recognized problem for this field
494 (Martin et al., 2024). For these studies, we applied an accepted approximation of ISPPA values as the sonic
495 wave passes through and loses much of its energy at the skull, whereby typically 70-75% of the intensity is
496 lost (Lee et al., 2015; Oghli et al., 2023). We compared these approximations to simulations using k-plan
497 software (Jaros et al., 2020; Treeby & Cox, 2010), targeting the same regions as in the reported experiments

498 with the reported ISPPA in water. Comparing the two values (k-plan simulations versus the approximated
499 derated values) showed a low margin of error of 5% between the two sets of values in the comparisons,
500 therefore we used the approximated values for studies not reporting ISPA in the brain.

501 Probable net enhancement versus suppression was characterized as follows. Although many studies
502 have reported behavioral influences, these alone are often not sufficient to determine neurobiological
503 effects, for the following reason. Although many studies may use sham control (e.g., no TUS), it is difficult
504 to rule out other sources for placebo effects in the behavioral reports. We thereby focused on the studies
505 reporting neurobiological effects and characterized these effects as probable net enhancement versus
506 suppression, using the following approach. For net enhancement, we followed the prior approach from the
507 TMS field whereby EEG-evoked responses that are magnified in the target area as a function of TUS
508 application can be characterized as probable enhancement (see Tables 1-2). We included positive fMRI
509 BOLD effects resulting from TUS as a probable enhancement. For suppression, we also followed the prior
510 approach from the TMS field whereby EEG evoked responses that were reduced indicate likely suppression.
511 Wherever possible, we relied on independently characterized directionality of effects, and cite the original
512 sources that conducted the characterization in Tables 1 and 2. As an example of a study categorized as
513 ‘suppression’ of function, Legon et al. (2014) examined TUS combined with EEG to modulate the primary
514 somatosensory cortex (S1) in healthy human subjects. The authors reported that TUS significantly
515 attenuated somatosensory evoked potentials. The effects were specific to the targeted region, because the
516 changes were abolished when the acoustic beam was focused away from S1. As another example, another
517 group that applied TUS to S1 of participants performing a sensory discrimination task reported augmented
518 somatosensory spatiotemporal EEG responses, interpreted as increased local excitability or ‘enhancement’
519 by our terminology (Liu et al., 2021).

520 The resulting data tables were submitted to a logistic regression model for testing with R Studio.
521 The R script used to generate the results from the data tables is shared as part of the resource developed in
522 the paper, see below. The first statistical model tested the NICE model predictions regarding ISPPA, Duty
523 Cycle and their interaction (logit ~ OfflineOnline + DC + Isspa + DC * Isspa). The sample sizes were 37
524 experimental observations, 35 error degrees of freedom. We also tested models including only ISPTA (as
525 the TUS ‘dose’ integrating the two parameters: ISPPA and DC), PRF or SD from the hypotheses. A single
526 model with all factors and all interactions would have been preferred but with these sample sizes does not
527 have sufficient degrees of freedom for evaluating so many factors and multi-level interactions in the same
528 model. This can be revisited in the future when sample sizes increase through the inTUS resource.

529 **Human TUS meta-analysis results.** The meta-analysis used the data in Tables 1 and 2. The tables
530 summarize the range of TUS parameters of interest for the studies reporting probable enhancement or
531 suppression of TUS effects, with the rationale for characterization of the directionality of TUS effects,
532 independently evaluated wherever possible as cited in Tables 1-2 rightmost column. These are further
533 separated by studies aiming to elicit online (Table 1) or offline effects (Table 2).

534 We first tested the NICE model predictions of TUS intensity (ISPPA in the brain) and DC. The
535 logistic regression with ISPPA in the brain, DC, and online/offline studies as factors were significantly
536 different from a constant model ($X^2 = 11.7, p = 0.020$). The statistical model showed a significant effect for
537 DC ($p = 0.046$), no significant effect for ISSPA ($p = 0.256$) and a statistical trend for a difference in the
538 Online and Offline study parameters used ($p = 0.061$)—as might be expected given the different parameters
539 that are often used for online and offline studies. The interaction of DC and ISPPA in the brain was not
540 significant ($p = 0.504$). The DC effect can be seen in Figure 4 as a greater than 0.6 likelihood for higher

541 DCs to be associated with enhancement. Lower duty cycles are more mixed and intensity does not seem to
542 be a strong explanatory factor or in interaction with DC. Lower DCs are more equally likely to lead to
543 enhancement or suppression. The other parameters of interest were not significant predictors with these
544 datasets for pulse repetition frequency (PRF: $p = 0.324$) or ISPTA ($p = 0.787$). However, sonication duration
545 was a significant predictor in the hypothesized direction (SD: $p = 0.04$), see Fig. 5.

546 Given the still limited sample size of human TUS studies to date, we interpret these meta-analysis
547 results with caution. A key observation is that the NICE model is not as strongly predictive as initially
548 evaluated (Dell'Italia et al., 2022; Zhang et al., 2023). Nonetheless, DC, in particular, may indeed be able
549 to tip the balance towards greater net enhancement for $DC > 20\%$ (Fig. 4A-C) or suppression for $DC <$
550 20% . The area of suppression (low duty cycles across the range of intensities) can, by these results, equally
551 often result in enhancement as suppression. Other parameters of interest are sonication duration (Thurman
552 et al., 2014), which has been highlighted in animal model recordings from excitatory and inhibitory neurons
553 to result in greater excitatory neuron activity at lower SDs (< 500 ms) or suppression with higher sonication
554 durations (> 500 ms) (Mihran et al., 1990; Tsui et al., 2005). The other takeaway point from the meta-
555 analysis is that many researchers are opting for lower DCs, presumably to ensure ISPTA values are not far
556 off the FDA threshold, associated in our results with suppression, highlighting a clear need for more
557 systematic exploration and computational modeling of the entire TUS parameter space.

558 *Theta Burst TUS for lasting neuromodulation:* Theta-burst TUS (tb-TUS) is being studied for its
559 capability to induce cortical LTP-like plasticity (Oghli et al 2023, Samuel et al. 2022, Samuel et al. 2023,
560 Zeng et al. 2022), which are identified in Table 2. For instance, tb-TUS consists of more continuous (than
561 typical online) stimulation, such as 80-second trains of 20-millisecond sonication pulses spaced over 200
562 milliseconds pulsed at a 4-8 Hz theta rhythm. These studies were too few to consider separately and were
563 included in the ‘offline’ studies for the meta-analysis (Table 2). As the number of tb-TUS studies grows, it
564 may be important to evaluate tb-TUS outcomes separately to other stimulation protocols.

565 **Meta-analysis limitations.** A key limitation of this meta-analysis is the relatively small sample size. Non-
566 categorical, data-driven or multi-variate analyses of these data are not currently possible, which would be
567 possible with greater sample sizes. Another limitation is the inherent selection bias of retrospective studies,
568 whereby researchers may limit their exploration of the TUS parameter space based on studies with positive
569 findings and/or those targeting similar behaviors and brain areas. Also, we and others have noted that few
570 TUS researchers, as a rule, share the full set of key parameters necessary for meta-analysis and secondary
571 hypothesis testing, even though the ITRUSST community has devised a list of parameters that all TUS
572 studies should aim to report (Martin et al., 2024). Thus, we had to simulate the derated ISPTA values in the
573 brain, warranting caution when interpreting these results. Therefore, these results need to be considered as
574 tentative and possible to stabilize or change with larger sample sizes. We report them here primarily to
575 encourage more systematic exploration and reporting of the TUS parameter space, complemented with
576 computational modeling to fill in the gaps in the empirical research. The meta-analysis, thus, is intended to
577 be re-evaluated in combination with a TUS parameters and outcome reporting resource, as follows.

578 **Establishing the inTUS resource.** To help to address these limitations, we establish the inTUS resource.
579 We have openly shared the data and tools on the Open Science Framework <https://osf.io/arqp8/>. This open
580 repository contains the data tables and the R script to regenerate the statistical tests and results, which can
581 be repeated as the data tables expand with input from future studies. The resource has a form that researchers
582 can complete to submit parameters and outcomes as part of their published work to be incorporated. We
583 encourage TUS researchers to contribute more accurate values, if these are missing, from their prior studies
584 and to more systematically report the more complete set of values in future. This will allow the data to be
585 mined more systematically, which may further support or refute these hypotheses, help to develop new ones

586 and better show the crucial interactions between parameters in relation to effects characterized in greater
587 depth than was possible here. We anticipate that this effort will dovetail with a need for further NICE and
588 other computational modeling. TUS effects could also be modeled across the cortical depth, in interaction
589 with other brain areas (Thorpe et al., 2024) or with the cellular properties of subcortical regions. We also
590 welcome input via the online form on improving the criteria for assessing neurobiological or behavioral
591 effects, which will benefit the entire TUS community and is a key objective of the ITRUSST consortium
592 <https://itrusst.com/>.

593 **Summary.** Given the sample size limitations, these retrospective meta-analysis results are tentative, with
594 the possibility that the results may stabilize or change. The combination of the meta-analysis and resource
595 are made openly available to further support and encourage the TUS research community to more
596 systematically report TUS parameters and study outcomes using the current or a more extended (e.g., data
597 driven, multi-variate) approach. Furthermore, we encourage the TUS research community to explore the
598 full parameter space whenever possible.

599 **BOXES**

PARAMETERS	DESCRIPTION	DEFINITION	UNITS
ISPPA	Intensity - Spatial Peak Pulse Average	Refers to the Average acoustic intensity	W/cm ²
ISPTA	Intensity - Spatial Peak Temporal Average	Temporally averaged intensity over the sonication duration (ISPPA * Duty Cycle)	W/cm ²
SD	Sonication Duration	Period during which TUS is applied to the brain target	Seconds
DC	Duty Cycle	Ratio of sonication on and off time	%
PRF	Pulse Repetition Frequency	The number of pulses per second delivered to the target	Hz
MI	Mechanical Index	Characterizes the likelihood of mechanical cavitation caused by TUS	
TI	Thermal Index	Estimate of temperature rise in tissue due to TUS exposure.	°C

600

601 **Box 1. Transcranial focused ultrasound stimulation (TUS) key parameters.** Shown are the
 602 abbreviations and measurement value definitions for the key TUS parameters.

603

FDA LIMITS FOR DIAGNOSTIC ULTRASOUND

ISPPA	$\leq 190 \text{ W/cm}^2$
ISPTA	$\leq 720 \text{ mW/cm}^2$
MI	≤ 1.9
TI	< 6

604

605 **Box 2. Recommendations for TUS parameters.** Currently, there are no established and universally
606 recognized guidelines for the safe application of TUS. Nevertheless, FDA guidelines exist for diagnostic
607 ultrasound, and as such much of the TUS literature has taken these limits into consideration. These are
608 summarized in the table above, see Box 1 for a description of these parameters. The International
609 Transcranial Ultrasonic Stimulation Safety and Standards (iTRUSST) consortium has recently established
610 recommendations based on existing guidelines for diagnostic ultrasound from regulatory bodies such as the
611 Food and Drug Administration (FDA), the British Medical Ultrasound Society (BMUS) and the American
612 Institute of Ultrasound in Medicine (AIUM). In brief the MI should be below 1.9 and temperature rise in
613 soft tissue below 2 degrees Celsius (<https://arxiv.org/abs/2311.05359>). Importantly, those
614 recommendations should be considered in parallel to individualized simulations to further reduce the risk
615 of adverse bioeffects.

616 **Directionality of TUS Hypotheses**


	Intensity (Isspa brain)	Sonication duration (SD)	Duty Cycle (DC)	Pulse Repetition Frequency (PRF)
Enhancement weighted	Higher intensity	<500 ms	> 30%	> 300 Hz
Suppression weighted	Lower intensity	>500 ms	< 30%	< 300 Hz

617 **Box 3. Net enhancement versus suppression hypotheses.** Summarized hypotheses on how net
618 enhancement or suppression could be biased with TUS parameters.

619

620

621 **FIGURES**




622

623 **Figure 1. Schematic overview of the specificity of brain perturbation techniques.** Brain perturbation
 624 techniques vary in the precision of the spatial and temporal effects that can be elicited, on logarithmic
 625 (log₁₀) scales. This includes transcranial Focused Ultrasound Stimulation (TUS), in green. Some
 626 approaches with cellular specificity are shown that are currently primarily in use with nonhuman
 627 animals as models (optogenetics, infrared neuromodulation, chemogenetics and genetic manipulation). Figure
 628 modified with permission from P.C. Klink, from (Klink et al., 2021).

629

630



631

632 **Figure 2. Low-intensity Transcranial Ultrasound Stimulation for Neuromodulation in Humans.** (A,
633 B, C) Example focal TUS targeting of a human motor cortex using k-plan software (BrainBox, Inc.) (D)
634 TUS simulation software uses an input set of parameters (e.g., pulse duration, PD, sonication duration,
635 pulse repetition frequency, PRF, transducer properties and fundamental frequency (FF), intensity in water
636 (ISSPA), to simulate and calculate the approximate TUS intensity in the target brain region using the
637 participant's MRI and CT scans if available, or template human brain and CT scans. Simulation software
638 will also generate the complete set of minimal parameters for reporting.

639

640

641

642

643

644

645

646

647

648

649


650

651

652

653

654




690 **Figure 3. Meta-analysis selection and inclusion criteria using the PRISMA recommended approach.**
691 Selection and inclusion criteria for the meta-analysis, with resulting sample sizes for the meta-analysis.

692

693

694




695

696

697 **Figure 4. Meta-analysis effects relative to NICE model predictions.** (A) Online effects meta-analysis
 698 based on the studies in Table 1, segregated by probable enhancement versus suppression. Light blue line
 699 shows the NICE model boundary between suppression and enhancement (potential net excitation). Blue
 700 circles are human studies reporting probable enhancement, red circles probable suppression. Index numbers
 701 correspond to studies numbered in Table 1. (B) Same format and analysis approach showing the “offline”
 702 effects studies in Table 2 with stars. Index numbers correspond to studies numbered in Table 2. (C)
 703 Combined figure with online (Table 1) and offline (Table 2) studies. Same symbol and color use as in A-
 704 B. (D) Additional hypothesized parameters like pulse repetition frequency (PRF) can be plotted in multi-
 705 dimensional spaces as shown.

706



707

708

709 **Figure 5. Box plots of meta-analysis results for the key TUS parameters.** Shown are boxplots for each
710 of the TUS parameters of interest segregated by probable enhancement or suppression (data from Tables 1
711 and 2). Plots show TUS parameters: Pulse Repetition Frequency (PRF), Duty Cycle, Sonication Duration,
712 ISPPA. These are shown separately for Online effects (A) and Offline effects (B). The logistic regression
713 only showed a significant effect for Duty Cycle, but we recognize that the results are underpowered at this
714 stage. (C) Shows results for ISPTA, the potential ultrasound ‘dose’ parameter that integrates ISPPA and
715 DC. This is shown for online (left panel), offline (middle panel) effects, and for ISPPA in the brain for both
716 offline and online effects combined (right panel)

717

ONLINE EFFECTS

PROBABLE ENHANCEMENT OF FUNCTIONS

STUDY	TARGET	FF (KHz)	PRF (Hz)	DC (%)	SD (sec)	PD (ms)	Isppa Water (W/cm2)	Ispta Brain (W/cm2)	Isppa Brain (W/cm2)	Reported Effect [independently characterized]
1. (Lee et al., 2015)	Hand Region S1	250	500	50	0.30	1	3	0.35	0.70	TUS enhanced somatosensory evoked potentials. [Wang et al. 2019]
2. (Lee et al., 2016a)	S2 and S2+S1	210	500	50	0.50	1	35	4.40	8.80	TUS elicited tactile sensations and enhanced somatosensory evoked potentials. [Wang et al. 2019; G. Darmani et al. 2022]
3. (Lee et al., 2016b)	V1	270	500	50	0.30	1	16.60	5.80	11.60	Simultaneous TUS and 3T fMRI resulted in increased BOLD signal in V1. With EEG: increased potentials (e.g., P100 and P200). Produced phosphene perception in some subjects. [Zhang et al. 2021]
4. (Ai et al., 2016) Exp 1 (3T)	Sensorimotor	500	1000	36	0.50	0.36	24	2.16	6	TUS in sensorimotor cortex led to focal BOLD activation. [Yüksel et al.(2023)]
5. (Ai et al., 2016) Exp 2 (7T)	Caudate	860	1000	50	0.50	0.5	24	3	6	TUS in caudate led to focal BOLD activation in subcortical areas. [Yüksel et al. (2023)]
6. (Ai et al., 2018)	M1 (thumb)	500	1000	36	0.50	0.36	16.95	1.52	4.23	Increased fMRI BOLD signal in motor cortex (M1) thumb representation during a cued tapping task. [Wang et al. 2019; Biase et al. 2019]
7. (Fine et al., 2020)	VLPFC	500	1000	24	0.50	0.24	22.40	1.34	5.60	TUS of right ventro-lateral PFC (VLPFC), enhanced frontal EEG potential (P300) for stop-trials in a stop signal task. (Enhanced inhibition action.) [Yüksel et al. (2023)]
8. (Yu et al., 2020a)	M1 (leg area)	500	3000	60	0.50	0.2	5.90	0.70	1.17	Increased movement-related cortical activity when compared to sham, with the highest PRF used. [Yüksel et al. (2023)]
9. (Liu et al., 2021)	S1	500	300	6	0.50	0.2	5.64	0.07	1.10	TUS increased local excitability of S1 area EEG responses during sensory discrimination tasks. Early and late phase EEG potentials were enhanced. N300 potential amplitude was also enhanced.
10. (Kuhn et al., 2023)	Entorhinal Cortex	650	100	5	30	0.5	57.60	0.72	14.40	Increased fMRI activity in entorhinal cortex and functional connectivity.
11. (Zhang et al., 2023)--> Exc	M1 (hand area)	500	2000	40	0.50	0.2	2.46	0.25	0.62	Excitatory protocol, combining TUS + TMS of motor cortex increased M1 excitability and decreased intracortical inhibition.
AVERAGE		476	991	37	3.2	0.5	19.4	1.9	5.5	

718

719

720

ONLINE EFFECTS		PROBABLE SUPPRESSION OF FUNCTION								
STUDY	TARGET	FF (KHz)	PRF (Hz)	DC (%)	SD (sec)	PD (ms)	Isppa Water (W/cm2)	Ispta Brain (W/cm2)	Isppa Brain (W/cm2)	Reported Effect [independently characterized]
12. (Legon et al., 2014)	S1	500	1000	36	0.50	0.36	23.9	2.2	6	TUS to S1 attenuates somatosensory evoked potentials. Improved tactile discrimination task performance.
13. (Mueller et al., 2014)	S1	500	1000	36	0.50	0.36	23.9	2.2	6	Disrupted intrinsic brain activity and phases for beta, not for gamma. [Zhang et al. 2021]
14. (Legon et al., 2018a)	Thalamus VPL	500	1000	36	0.50	0.36	14.5	2.53	7.03	Attenuation of somatosensory evoked component. Attenuation of alpha and beta power. [Zhang et al. 2021]
15. (Legon et al., 2018b)	M1	500	1000	36	0.50	0.36	17.12	1.54	4.28	Attenuation of motor evoked potential during single-pulse TMS. Attenuation of intracortical facilitation (ICF), unaffected SICI.
16. (Fomenko et al., 2020)	M1	500	1000	10	0.50	0.1	9.28	0.69	2.32	TMS motor evoked potential suppression in a dose-dependent manner and increase in short interval intracortical inhibition. [Zhang et al. 2021; Yüksel et al. (2023)]
17. (Cain et al., 2021b)--> Mode 1	Globus Pallidus	650	100	5	30	0.5	57.6	0.72	14.40	TUS decreased fMRI BOLD signal and within the brain network observed.
18. (Xia et al., 2021)	M1	500	1000	30	0.50	0.3	9.26	0.69	2.32	Inhibition of ipsilateral M1 potential after TUS.
19. (Butler et al., 2022)	Visual Cortex (area MT)	500	1000	50	0.30	0.5	5.76	0.72	1.44	TUS to visual area hMT+ produced attenuation of visual motion EEG evoked potentials.
20. (Kuhn et al., 2023)	Amygdala	650	10	5	30	5	57.6	0.72	14.40	Decreased functional inter-connectivity with amygdala.
21. (Zhang et al., 2023) --> Inhibitory TUS	M1 (hand area)	500	50	2	0.50	0.4	2.46	0.01	0.62	Inhibitory protocol: TUS + TMS --> Increased short and long interval intracortical inhibition with reduced intracortical facilitation.
AVERAGE		530	716	24.6	6.4	0.8	22.1	1.2	5.9	

721 **Table 1. Human ‘online’ effect TUS studies categorized by probable enhancement or suppression.** Summarized are the TUS parameters
722 reported in human studies focusing on inducing online effects and their reported neurobiological effects summarized by likely excitatory or
723 inhibitory effects. Independently confirmed effects cite the independent assessment source.

OFFLINE EFFECTS		PROBABLE ENHANCEMENT OF FUNCTION								
STUDY	TARGET	FF (KHz)	PRF (Hz)	DC (%)	SD (sec)	PD (ms)	Isppa Water (W/cm2)	Ispta Brain (W/cm2)	Isppa Brain (W/cm2)	Reported Effect [independently characterized]
1. (Monti et al., 2016)	Thalamus	650	100	5	30	0.50	57.60	0.72	14.40	One patient case study. Emergence from minimally conscious state three days after sonication. Recovery of motor and oromotor functions and full language comprehension.
2. (Y. Zhang et al., 2021)	Motor Cortex	500	100	5	0.5	0.50	8.05	0.14	2.84	TUS induced modulation of TMS motor evoked potentials, lasted 30 min. Improved stop signal task performance. [Yüksel et al. (2023)]
3. (Zeng et al., 2022) tbTUS protocol	left M1	500	5	10	80	20.00	2.26	0.057	0.57	Their Theta-burs TUS protocol: TUS + TMS increased corticospinal excitability, increased intracortical facilitation and decreased short interval intracortical inhibition. LTP-like effects lasted 30 to 60 min. [C. Sarica et al. 2022]
4. (Zeng et al., 2022) rTUS protocol	M1	500	1000	32	0.5	0.32	2.30	0.184	0.58	Their rTUS protocol: Increased TMS motor evoked potentials. [C. Sarica et al. 2022]
5. (Samuel et al., 2022) tbTUS protocol	M1	500	5	10	80	20.00	2.26	0.057	0.57	TUS + TMS tbTUS protocol, increased motor evoked potentials, decreased short interval intracortical inhibition, and no changes in intracortical facilitation.
6. (Ren et al., 2023)	M1	500	100	5	0.5	0.50	8.09	0.10	2.02	TUS induced LTP-like plasticity in ipsilateral M1. Interhemispheric balance of M1 excitability modulated by TUS.
7. (Zhai et al., 2023) rTUS protocol	IDLPC	500	100	5	0.5	0.50	8.09	0.10	2.02	TMS motor evoked potentials increased significantly after rTUS protocol to DLPFC, inducing LTP-like plasticity. Alleviated negative symptoms and improved cognitive performance in schizophrenic patients.
8. (Bault et al., 2023)	dACC & PCC	500	5	10	80	20.00	33.80	1.50	15	Reduction in GABA levels in the posterior cingulate cortex (PCC) lasted 30 min. Increase rsfMRI connectivity in dorsal anterior cingulate cortex (dACC) & PCC lasted 50 min. TUS on PCC increased functional connectivity with the dACC.
9. (Kim et al., 2023)	S1	250	1400	70	0.2	0.50	14.70	2.90	4.10	This study produced evoked EEG TUS responses like somatosensory evoked potentials as well as resting-state functional connectivity changes that outlasted the sonication for 1 hour.
10. (Kim et al., 2023)	VPL	250	1400	70	0.2	0.50	9.10	2.40	3.40	
AVERAGE		465	422	22.2	27.2	6.3	14.6	0.8	4.6	

OFFLINE EFFECTS											PROBABLE SUPPRESSION OF FUNCTION										
STUDY	TARGET	FF (KHz)	PRF (Hz)	DC (%)	SD (sec)	PD (ms)	Isppa Water (W/cm2)	Ispta Brain (W/cm2)	Isppa Brain (W/cm2)	Reported Effect [independently characterized]											
11. (Badran et al., 2020)	Anterior Thalamus	650	10	5	30	5	57.52	0.72	14.38	Significant reduction of thermal pain sensitivity. TUS-induced antinociceptive effects. [Yüksel et al. (2023)]											
12. (Sanguinetti et al., 2020)	Fronto-Temporal Cortex	500	40	0.5	30	0.13	54	0.07	13.5	Decrease in functional connectivity (rsfMRI) in resting state network between right Inferior Frontal Gyrus and left limbic areas. Increased FC between rIFG and rMFG.											
13. (Cain et al., 2022)	Central Thalamus	650	100	5	30	0.5	57.60	0.72	14.4	BOLD signal decreased in Frontal Cortex and Basal Ganglia. [Yüksel et al. (2023)]											
14. (Forster et al., 2023a)	I(PFG)	500	40	0.5	120	0.13	160	0.20	40	Decrease in EEG mid-frontal theta which lasted up to 90 min post-TUS.											
15. (Forster et al., 2023b)	IFG	500	40	0.5	120	0.13	160	0.20	40	Inhibition of rIFG											
16. (Oghli et al., 2023) tbTUS protocol	M1 (hand area)	500	5	10	80	20	11.73	0.29	2.90	tbTUS plasticity effects reduced by channel blockers.											
AVERAGE		550	39.2	3.6	68.3	4.3	83.5	0.4	20.9												

725 **Table 2. Human ‘offline’ effect TUS studies categorized by probable enhancement or suppression.** Summarized are the TUS parameters used
726 in human studies focusing on inducing longer lasting or ‘offline’ effects.

727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764

Introduction to the inTUS Resource: Iowa Newcastle

focused Transcranial Ultrasound Stimulation Resource

The Iowa Newcastle human low-intensity TUS Resource consists of the following resource items, linked to Caffaratti et al. *Neuromodulation with Ultrasound: Hypotheses on the Directionality of Effects and a Community Resource*.

The resource documents can be found on the Laboratory of Comparative Neuropsychology data share on Open Science Framework: <https://osf.io/arqp8/> under Cafferatti_et_al_inTUS_Resource.

Resource documents:

- **Data Tables for Offline and Online Effects** – Tables_Online_Offline_Effects.xlsx, these will continue to be updated by the corresponding authors, please email us the parameters needed to populate the table for your experiment or use the Google Forms link below to submit your values.
- **R-Script** to generate the figures and statistical tests using R Studio
 - Rmd_Output_06_24.pdf is an example output file generated 6-24
 - Rmd_TUS_Effects_06_24.Rmd is an executable R script
 - Table_R_version_06_24.csv is the R readable data spreadsheet
- **Matlab GUI:** created by Ryan Calmus for controlling the NeuroFUS system.
- **Qualtrics Form** to submit your own data to be added by the corresponding authors.

Please find link to the form below:

- https://uiowa.qualtrics.com/jfe/form/SV_4VOvb0fdwvACDkO

Using the resource:

To regenerate the manuscript figures with the latest tables, Download the *R data table* and *R_script*. Run it in RStudio, making sure it can access the latest data table.

Contributing to the resource:

Please use the Qualtrics Link and Form to submit your preprint or published paper values. These will be checked in relation to your paper and once verified will be input into the data tables. The link is also available here: https://uiowa.qualtrics.com/jfe/form/SV_4VOvb0fdwvACDkO

Only humans?

This resource was established with human low-intensity tFUS studies. We will be working on the resource being extended to nonhuman animals of different species. Please use the Qualtrics Form if you're interested or have suggestions about non-human animal data contributing to the resource.

765 **Acknowledgements**

766 Supported by National Institutes of Health USA (R01–DC04290), National Science Foundation (2342847)
767 and Medical Research Council (UK). Ben Slater is supported by a BBSRC UK PhD studentship. M.K. was
768 supported by the Engineering and Physical Sciences Research Council (EP/W004488/1 and
769 EP/X01925X/1) and the Guangci Professorship Program of Rui Jin Hospital (Shanghai Jiao Tong
770 University)

771

772 **Competing interests statement**

773 The authors declare no competing or financial interests.

774

775 **Data availability**

776 The datasets and R script generated in this study have been deposited in the Open Science Framework
777 <https://osf.io/arqp8/> in the Caffaratti_et_al_inTUS_Resource folder.

778 **REFERENCES**

779

- 780 Abe, K., Yamaguchi, T., Hori, H., Sumi, M., Horisawa, S., Taira, T., & Hori, T. (2020). Magnetic
781 resonance-guided focused ultrasound for mesial temporal lobe epilepsy: a case report. *BMC*
782 *neurology*, 20(1).
- 783 Ai, L., Bansal, P., Mueller, J. K., & Legon, W. (2018). Effects of transcranial focused ultrasound on human
784 primary motor cortex using 7T fMRI: a pilot study. *BMC Neuroscience*, 19, 1-10.
- 785 Ai, L., Mueller, J. K., Grant, A., Eryaman, Y., & Legon, W. (2016). Transcranial focused ultrasound for
786 BOLD fMRI signal modulation in humans. 2016 38th Annual International Conference of the IEEE
787 Engineering in Medicine and Biology Society (EMBC),
- 788 Anishkin, A., Loukin, S. H., Teng, J., & Kung, C. (2014). Feeling the hidden mechanical forces in lipid
789 bilayer is an original sense. *Proceedings of the National Academy of Sciences*, 111(22), 7898-7905.
- 790 Babakhanian, M., Yang, L., Nowroozi, B., Saddik, G., Boodaghians, L., Blount, P., & Grundfest, W.
791 (2018). Effects of low intensity focused ultrasound on liposomes containing channel proteins.
792 *Scientific reports*, 8(1), 17250.
- 793 Badran, B. W., Caulfield, K. A., Stomberg-Firestein, S., Summers, P. M., Dowdle, L. T., Savoca, M., Li,
794 X., Austelle, C. W., Short, E. B., & Borckardt, J. J. (2020). Sonication of the anterior thalamus with
795 MRI-Guided transcranial focused ultrasound (tFUS) alters pain thresholds in healthy adults: A
796 double-blind, sham-controlled study. *Brain Stimulation*, 13(6), 1805-1812.
- 797 Baek, H., Pahk, K. J., & Kim, H. (2017). A review of low-intensity focused ultrasound for neuromodulation.
798 *Biomedical engineering letters*, 7(2), 135-142.
- 799 Bateman, L. M., Li, C.-S., & Seyal, M. (2008). Ictal hypoxemia in localization-related epilepsy: analysis
800 of incidence, severity and risk factors. *Brain*, 131(12), 3239-3245.
- 801 Bault, N., Yaakub, S. N., & Fouragnan, E. (2023). Early-phase neuroplasticity induced by offline
802 transcranial ultrasound stimulation in primates.
- 803 Beisteiner, R., Matt, E., Fan, C., Baldysiak, H., Schönfeld, M., Philippi Novak, T., Amini, A., Aslan, T.,
804 Reinecke, R., Lehrner, J., Weber, A., Reime, U., Goldenstedt, C., Marlinghaus, E., Hallett, M., &
805 Lohse-Busch, H. (2020). Transcranial Pulse Stimulation with Ultrasound in Alzheimer's Disease—
806 A New Navigated Focal Brain Therapy. *Advanced Science*, 7(3).
- 807 Benzagmout, M., Gatignol, P., & Duffau, H. (2007). Resection of world health organization grade II
808 gliomas involving Broca's area: Methodological and functional considerations. *Neurosurgery*,
809 61(4), 741-752.
- 810 Blackmore, D. G., Razansky, D., & Götz, J. (2023). Ultrasound as a versatile tool for short- and long-term
811 improvement and monitoring of brain function. *Neuron*, 111(8), 1174-1190.
- 812 Bretsztajn, L., & Gedroyc, W. (2018). Brain-focussed ultrasound: what's the "FUS" all about? A review of
813 current and emerging neurological applications. *The British journal of radiology*, 91(1087),
814 20170481.
- 815 Brinker, S. T., Preiswerk, F., White, P. J., Mariano, T. Y., McDannold, N. J., & Bubrick, E. J. (2020).
816 Focused Ultrasound Platform for Investigating Therapeutic Neuromodulation Across the Human
817 Hippocampus. *Ultrasound in medicine & biology*, 46(5), 1270-1274.

- 818 Bubrick, E. J., McDannold, N. J., Orozco, J., Mariano, T. Y., Rigolo, L., Golby, A. J., Tie, Y., & White, P.
819 J. (2024). Transcranial ultrasound neuromodulation for epilepsy: A pilot safety trial. *Brain*
820 *Stimulation: Basic, Translational, and Clinical Research in Neuromodulation*, 17(1), 7-9.
- 821 Butler, C. R., Rhodes, E., Blackmore, J., Cheng, X., Peach, R. L., Veldsman, M., Sheerin, F., & Cleveland,
822 R. O. (2022). Transcranial ultrasound stimulation to human middle temporal complex improves
823 visual motion detection and modulates electrophysiological responses. *Brain Stimulation*, 15(5),
824 1236-1245.
- 825 Cain, J. A., Spivak, N. M., Coetzee, J. P., Crone, J. S., Johnson, M. A., Lutkenhoff, E. S., Real, C., Buitrago-
826 Blanco, M., Vespa, P. M., & Schnakers, C. (2022). Ultrasonic deep brain neuromodulation in acute
827 disorders of consciousness: a proof-of-concept. *Brain Sciences*, 12(4), 428.
- 828 Cain, J. A., Visagan, S., Johnson, M. A., Crone, J., Blades, R., Spivak, N. M., Shattuck, D. W., & Monti,
829 M. M. (2021). Real time and delayed effects of subcortical low intensity focused ultrasound.
830 *Scientific reports*, 11(1), 6100.
- 831 Chang, E. F., Raygor, K. P., & Berger, M. S. (2015). Contemporary model of language organization: an
832 overview for neurosurgeons. *Journal of neurosurgery*, 122(2), 250-261.
- 833 Chang, W. S., Jung, H. H., Kweon, E. J., Zadicario, E., Rachmilevitch, I., & Chang, J. W. (2015). Unilateral
834 magnetic resonance guided focused ultrasound thalamotomy for essential tremor: practices and
835 clinicoradiological outcomes. *Journal of Neurology, Neurosurgery & Psychiatry*, 86(3), 257-264.
- 836 Chen, C.-M., Wu, C.-T., Yang, T.-H., Liu, S.-H., & Yang, F.-Y. (2018). Preventive effect of low intensity
837 pulsed ultrasound against experimental cerebral ischemia/reperfusion injury via apoptosis
838 reduction and brain-derived neurotrophic factor induction. *Scientific reports*, 8(1), 5568.
- 839 Chen, R., Classen, J., Gerloff, C., Celnik, P., Wassermann, E. M., Hallett, M., & Cohen, L. G. (1997).
840 Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation.
841 *Neurology*, 48(5), 1398-1403.
- 842 Choi, K.-H., & Kim, J.-H. (2019). Therapeutic applications of ultrasound in neurological diseases. *Journal*
843 *of Neurosonology and Neuroimaging*, 11(1), 62-72.
- 844 Chu, P.-C., Liu, H.-L., Lai, H.-Y., Lin, C.-Y., Tsai, H.-C., & Pei, Y.-C. (2015). Neuromodulation
845 accompanying focused ultrasound-induced blood-brain barrier opening. *Scientific reports*, 5(1),
846 15477.
- 847 Chudy, D., Deletis, V., Paradžik, V., Dubroja, I., Marčinković, P., Orešković, D., Chudy, H., & Raguž, M.
848 (2023). Deep brain stimulation in disorders of consciousness: 10 years of a single center experience.
849 *Scientific reports*, 13(1), 19491.
- 850 Cornelssen, C., Finlinson, E., Rolston, J. D., & Wilcox, K. S. (2023). Ultrasonic therapies for seizures and
851 drug-resistant epilepsy. *Frontiers in neurology*, 14, 1301956.
- 852 Daffertshofer, M., Gass, A., Ringleb, P., Sitzer, M., Sliwka, U., Els, T., Sedlaczek, O., Koroshetz, W. J., &
853 Hennerici, M. G. (2005). Transcranial Low-Frequency Ultrasound-Mediated Thrombolysis in
854 Brain Ischemia. *Stroke*, 36(7), 1441-1446.
- 855 Dallapiazza, R. F., Timbie, K. F., Holmberg, S., Gatesman, J., Lopes, M. B., Price, R. J., Miller, G. W., &
856 Elias, W. J. (2017). Noninvasive neuromodulation and thalamic mapping with low-intensity
857 focused ultrasound. *Journal of neurosurgery*, 128(3), 875-884.
- 858 Darmani, G., Bergmann, T., Pauly, K. B., Caskey, C., De Lecea, L., Fomenko, A., Fouragnan, E., Legon,
859 W., Murphy, K., & Nandi, T. (2022). Non-invasive transcranial ultrasound stimulation for
860 neuromodulation. *Clinical Neurophysiology*, 135, 51-73.

- 861 Deffieux, T., Wattiez, N., Tanter, M., Pouget, P., Aubry, J.-F., & Younan, Y. (2015). Low intensity focused
862 ultrasound modulates monkey visuomotor behavior. *Journal of therapeutic ultrasound*, 3(1), 1-2.
- 863 Deffieux, T., Younan, Y., Wattiez, N., Tanter, M., Pouget, P., & Aubry, J.-F. (2013). Low-intensity focused
864 ultrasound modulates monkey visuomotor behavior. *Current Biology*, 23(23), 2430-2433.
- 865 Dell'Italia, J., Sanguinetti, J. L., Monti, M. M., Bystritsky, A., & Reggente, N. (2022). Current state of
866 potential mechanisms supporting low intensity focused ultrasound for neuromodulation. *Frontiers*
867 *in Human Neuroscience*, 16, 872639.
- 868 Derosiere, G., Vassiliadis, P., & Duque, J. (2020). Advanced TMS approaches to probe corticospinal
869 excitability during action preparation. *NeuroImage*, 213, 116746.
- 870 Dlouhy, B. J., Gehlbach, B. K., Kreple, C. J., Kawasaki, H., Oya, H., Buzza, C., Granner, M. A., Welsh,
871 M. J., Howard, M. A., & Wemmie, J. A. (2015). Breathing inhibited when seizures spread to the
872 amygdala and upon amygdala stimulation. *Journal of Neuroscience*, 35(28), 10281-10289.
- 873 Duffau, H. (2010). Awake surgery for nonlanguage mapping. *Neurosurgery*, 66(3), 523-528.
- 874 Elias, W. J., Huss, D., Voss, T., Loomba, J., Khaled, M., Zadicario, E., Frysinger, R. C., Sperling, S. A.,
875 Wylie, S., Monteith, S. J., Druzgal, J., Shah, B. B., Harrison, M., & Wintermark, M. (2013). A Pilot
876 Study of Focused Ultrasound Thalamotomy for Essential Tremor. *New England Journal of*
877 *Medicine*, 369(7), 640-648.
- 878 Elias, W. J., Lipsman, N., Ondo, W. G., Ghanouni, P., Kim, Y. G., Lee, W., Schwartz, M., Hynynen, K.,
879 Lozano, A. M., Shah, B. B., Huss, D., Dallapiazza, R. F., Gwinn, R., Witt, J., Ro, S., Eisenberg, H.
880 M., Fishman, P. S., Gandhi, D., Halpern, C. H., . . . Chang, J. W. (2016). A Randomized Trial of
881 Focused Ultrasound Thalamotomy for Essential Tremor. *The New England journal of medicine*,
882 375(8), 730-739.
- 883 Ficker, D. M., So, E., Shen, W., Annegers, J., O'Brien, P., Cascino, G., & Belau, P. (1998). Population-
884 based study of the incidence of sudden unexplained death in epilepsy. *Neurology*, 51(5), 1270-
885 1274.
- 886 Fine, J. M., Fini, M. E., Mysore, A. S., Tyler, W. J., & Santello, M. (2020). Response inhibition is driven
887 by top-down network mechanisms and enhanced with focused ultrasound. *BioRxiv*.
- 888 Fitzgerald, P. B., Fountain, S., & Daskalakis, Z. J. (2006). A comprehensive review of the effects of rTMS
889 on motor cortical excitability and inhibition. *Clinical neurophysiology : official journal of the*
890 *International Federation of Clinical Neurophysiology*, 117(12), 2584-2596.
- 891 Fomenko, A., Chen, K.-H. S., Nankoo, J.-F., Saravanamuttu, J., Wang, Y., El-Baba, M., Xia, X., Seerala,
892 S. S., Hynynen, K., & Lozano, A. M. (2020). Systematic examination of low-intensity ultrasound
893 parameters on human motor cortex excitability and behavior. *eLife*, 9, e54497.
- 894 Food & Drug Administration. (2019). Marketing clearance of diagnostic ultrasound systems and
895 transducers. *Guidance for Industry and Food and Drug Administration Staff. Available online:*
896 *<https://www.fda.gov/media/71100/download> (accessed on 19 April 2021).*
- 897 Forster, A., Rodrigues, J., Ziebell, P., Sanguinetti, J. L., Allen, J. J., & Hewig, J. (2023a). Transcranial
898 focused ultrasound modulates the emergence of learned helplessness via midline theta
899 modification. *Journal of Affective Disorders*, 329, 273-284.
- 900 Forster, A., Rodrigues, J., Ziebell, P., Sanguinetti, J. L., Allen, J. J., & Hewig, J. (2023b). Investigating the
901 role of the right inferior frontal gyrus in control perception: a double-blind cross-over study using
902 ultrasonic neuromodulation. *Neuropsychologia*, 187, 108589.

- 903 Gaur, P., Casey, K. M., Kubanek, J., Li, N., Mohammadjavadi, M., Saenz, Y., Glover, G. H., Bouley, D.
904 M., & Pauly, K. B. (2020). Histologic safety of transcranial focused ultrasound neuromodulation
905 and magnetic resonance acoustic radiation force imaging in rhesus macaques and sheep. *Brain*
906 *Stimulation*, *13*(3), 804-814.
- 907 Gibson, B. C., Sanguinetti, J. L., Badran, B. W., Yu, A. B., Klein, E. P., Abbott, C. C., Hansberger, J. T.,
908 & Clark, V. P. (2018). Increased excitability induced in the primary motor cortex by transcranial
909 ultrasound stimulation. *Frontiers in neurology*, *9*, 1007.
- 910 Guerra, A., Vicenzini, E., Cioffi, E., Colella, D., Cannavacciuolo, A., Pozzi, S., Caccia, B., Paparella, G.,
911 Di Stefano, G., & Berardelli, A. (2021). Effects of transcranial ultrasound stimulation on trigeminal
912 blink reflex excitability. *Brain Sciences*, *11*(5), 645.
- 913 Hameroff, S., Trakas, M., Duffield, C., Annabi, E., Gerace, M. B., Boyle, P., Lucas, A., Amos, Q., Buadu,
914 A., & Badal, J. J. (2013). Transcranial ultrasound (TUS) effects on mental states: a pilot study.
915 *Brain Stimulation*, *6*(3), 409-415.
- 916 Hanawa, K., Ito, K., Aizawa, K., Shindo, T., Nishimiya, K., Hasebe, Y., Tuburaya, R., Hasegawa, H.,
917 Yasuda, S., & Kanai, H. (2014). Low-intensity pulsed ultrasound induces angiogenesis and
918 ameliorates left ventricular dysfunction in a porcine model of chronic myocardial ischemia. *PLoS*
919 *One*, *9*(8), e104863.
- 920 Harmata, G. I., Rhone, A. E., Kovach, C. K., Kumar, S., Mowla, M. R., Sainju, R. K., Nagahama, Y., Oya,
921 H., Gehlbach, B. K., & Ciliberto, M. A. (2023). Failure to breathe persists without air hunger or
922 alarm following amygdala seizures. *JCI insight*, *8*(22).
- 923 Hynynen, K., McDannold, N., Vykhodtseva, N., Raymond, S., Weissleder, R., Jolesz, F. A., & Sheikov, N.
924 (2006). Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for
925 molecular imaging and targeted drug delivery. *Journal of neurosurgery*, *105*(3), 445-454.
- 926 Ichijo, S., Shindo, T., Eguchi, K., Monma, Y., Nakata, T., Morisue, Y., Kanai, H., Osumi, N., Yasuda, S.,
927 & Shimokawa, H. (2021). Low-intensity pulsed ultrasound therapy promotes recovery from stroke
928 by enhancing angio-neurogenesis in mice in vivo. *Scientific reports*, *11*(1), 4958.
- 929 Imashiro, C., Azuma, T., Itai, S., Kuribara, T., Totani, K., Onoe, H., & Takemura, K. (2021). Travelling
930 ultrasound promotes vasculogenesis of three-dimensional-monocultured human umbilical vein
931 endothelial cells. *Biotechnology and bioengineering*, *118*(10), 3760-3769.
- 932 Jaros, M., Treeby, B. E., Georgiou, P., & Jaros, J. (2020). k-Dispatch: a workflow management system for
933 the automated execution of biomedical ultrasound simulations on remote computing resources.
934 *Proceedings of the Platform for Advanced Scientific Computing Conference*,
- 935 Jeong, H., Im, J. J., Park, J.-S., Na, S.-H., Lee, W., Yoo, S.-S., Song, I.-U., & Chung, Y.-A. (2021). A pilot
936 clinical study of low-intensity transcranial focused ultrasound in Alzheimer's disease.
937 *Ultrasonography*, *40*(4), 512.
- 938 Jeong, H., Song, I.-U., Chung, Y.-A., Park, J.-S., Na, S.-H., Im, J. J., Bikson, M., Lee, W., & Yoo, S.-S.
939 (2022). Short-term efficacy of transcranial focused ultrasound to the hippocampus in Alzheimer's
940 disease: A preliminary study. *Journal of Personalized Medicine*, *12*(2), 250.
- 941 Ji, N., Lin, W. H., Chen, F., Xu, L., Huang, J., & Li, G. (2020). Blood Pressure Modulation With Low-
942 Intensity Focused Ultrasound Stimulation to the Vagus Nerve: A Pilot Animal Study. *Frontiers in*
943 *Neuroscience*, *14*.

- 944 Johnston, S. C., Horn, J. K., Valente, J., & Simon, R. P. (1995). The role of hypoventilation in a sheep
945 model of epileptic sudden death. *Annals of Neurology: Official Journal of the American*
946 *Neurological Association and the Child Neurology Society*, 37(4), 531-537.
- 947 Katsanos, A. H., Alexandrov, A. V., Mandava, P., Köhrmann, M., Soinne, L., Barreto, A. D., Sharma, V.
948 K., Mikulik, R., Muir, K. W., Rothlisberger, T., Grotta, J. C., Levi, C. R., Molina, C. A., Saqqur,
949 M., Palaiodimou, L., Psaltopoulou, T., Vosko, M. R., Moreira, T., Fiebach, J. B., . . . Tsvigoulis,
950 G. (2020). Pulse pressure variability is associated with unfavorable outcomes in acute ischaemic
951 stroke patients treated with intravenous thrombolysis. *European Journal of Neurology*, 27(12),
952 2453-2462.
- 953 Kim, H.-C., Lee, W., Weisholtz, D. S., & Yoo, S.-S. (2023). Transcranial focused ultrasound stimulation
954 of cortical and thalamic somatosensory areas in human. *PLoS One*, 18(7), e0288654.
- 955 Kim, M. G., Kamimura, H. A., Lee, S. A., Aurup, C., Kwon, N., & Konofagou, E. E. (2020). Image-guided
956 focused ultrasound modulates electrically evoked motor neuronal activity in the mouse peripheral
957 nervous system in vivo. *Journal of neural engineering*, 17(2), 026026.
- 958 Kim, T., Park, C., Chhatbar, P. Y., Feld, J., Mac Grory, B., Nam, C. S., Wang, P., Chen, M., Jiang, X., &
959 Feng, W. (2021). Effect of Low Intensity Transcranial Ultrasound Stimulation on Neuromodulation
960 in Animals and Humans: An Updated Systematic Review. *Frontiers in Neuroscience*, 15, 620863-
961 620863.
- 962 King, R. L., Brown, J. R., & Pauly, K. B. (2014). Localization of ultrasound-induced in vivo
963 neurostimulation in the mouse model. *Ultrasound in medicine & biology*, 40(7), 1512-1522.
- 964 Klink, P. C., Aubry, J.-F., Ferrera, V. P., Fox, A. S., Froudust-Walsh, S., Jarraya, B., Konofagou, E. E.,
965 Krauzlis, R. J., Messinger, A., & Mitchell, A. S. (2021). Combining brain perturbation and
966 neuroimaging in non-human primates. *NeuroImage*, 235, 118017.
- 967 Kløvgaard, M., Sabers, A., & Ryvlin, P. (2022). Update on sudden unexpected death in epilepsy.
968 *Neurologic Clinics*, 40(4), 741-754.
- 969 Krishna, V., Sammartino, F., & Rezai, A. (2018). A review of the current therapies, challenges, and future
970 directions of transcranial focused ultrasound technology: advances in diagnosis and treatment.
971 *JAMA neurology*, 75(2), 246-254.
- 972 Kuhn, T., Spivak, N. M., Dang, B. H., Becerra, S., Halavi, S. E., Rotstein, N., Rosenberg, B. M., Hiller, S.,
973 Swenson, A., & Cvijanovic, L. (2023). Transcranial focused ultrasound selectively increases
974 perfusion and modulates functional connectivity of deep brain regions in humans. *Frontiers in*
975 *Neural Circuits*, 17, 1120410.
- 976 Lacuey, N., Zonjy, B., Londono, L., & Lhatoo, S. D. (2017). Amygdala and hippocampus are
977 symptomatogenic zones for central apneic seizures. *Neurology*, 88(7), 701-705.
- 978 Lee, C. C., Chou, C. C., Hsiao, F. J., Chen, Y. H., Lin, C. F., Chen, C. J., Peng, S. J., Liu, H. L., & Yu, H.
979 Y. (2022). Pilot study of focused ultrasound for drug-resistant epilepsy. *Epilepsia*, 63(1), 162-175.
- 980 Lee, W., Chung, Y. A., Jung, Y., Song, I. U., & Yoo, S. S. (2016a). Simultaneous acoustic stimulation of
981 human primary and secondary somatosensory cortices using transcranial focused ultrasound. *BMC*
982 *Neuroscience*, 17(1), 1-11.
- 983 Lee, W., Croce, P., Margolin, R. W., Cammalleri, A., Yoon, K., & Yoo, S. S. (2018). Transcranial focused
984 ultrasound stimulation of motor cortical areas in freely-moving awake rats. *BMC Neuroscience*,
985 19(1), 1-14.

- 986 Lee, W., Kim, H.-C., Jung, Y., Chung, Y. A., Song, I.-U., Lee, J.-H., & Yoo, S.-S. (2016b). Transcranial
987 focused ultrasound stimulation of human primary visual cortex. *Scientific reports*, 6(1), 34026.
- 988 Lee, W., Kim, H., Jung, Y., Song, I. U., Chung, Y. A., & Yoo, S. S. (2015). Image-guided transcranial
989 focused ultrasound stimulates human primary somatosensory cortex. *Scientific reports*, 5.
- 990 Lee, W., Weisholtz, D. S., Strangman, G. E., & Yoo, S.-S. (2021). Safety Review and Perspectives of
991 Transcranial Focused Ultrasound Brain Stimulation. *Brain & NeuroRehabilitation*, 14(1).
- 992 Legon, W., Ai, L., Bansal, P., & Mueller, J. K. (2018a). Neuromodulation with single-element transcranial
993 focused ultrasound in human thalamus. *Human brain mapping*, 39(5), 1995-2006.
- 994 Legon, W., Bansal, P., Tyshynsky, R., Ai, L., & Mueller, J. K. (2018b). Transcranial focused ultrasound
995 neuromodulation of the human primary motor cortex. *Scientific reports*, 8(1), 10007.
- 996 Legon, W., Sato, T. F., Opitz, A., Mueller, J., Barbour, A., Williams, A., & Tyler, W. J. (2014). Transcranial
997 focused ultrasound modulates the activity of primary somatosensory cortex in humans. *17(2)*, 322-
998 329.
- 999 Li, D., Cao, F., Han, J., Wang, M., Lai, C., Zhang, J., Xu, T., Bouakaz, A., Wan, M., Ren, P., & Zhang, S.
1000 (2023). The sustainable antihypertensive and target organ damage protective effect of transcranial
1001 focused ultrasound stimulation in spontaneously hypertensive rats. *Journal of Hypertension*, 41(5),
1002 852-866.
- 1003 Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert,
1004 I., Boutet, A., Smith, G. S., Hynynen, K., & Black, S. E. (2018). Blood-brain barrier opening in
1005 Alzheimer's disease using MR-guided focused ultrasound. *Nature Communications 2018 9:1*, 9(1),
1006 1-8.
- 1007 Lipsman, N., Schwartz, M. L., Huang, Y., Lee, L., Sankar, T., Chapman, M., Hynynen, K., & Lozano, A.
1008 M. (2013). MR-guided focused ultrasound thalamotomy for essential tremor: A proof-of-concept
1009 study. *The Lancet Neurology*, 12(5), 462-468.
- 1010 Liu, C., Yu, K., Niu, X., & He, B. (2021). Transcranial focused ultrasound enhances sensory discrimination
1011 capability through somatosensory cortical excitation. *Ultrasound in medicine & biology*, 47(5),
1012 1356-1366.
- 1013 Liu, D., Munoz, F., Sanatkhani, S., Pouliopoulos, A. N., Konofagou, E. E., Grinband, J., & Ferrera, V. P.
1014 (2023). Alteration of functional connectivity in the cortex and major brain networks of non-human
1015 primates following focused ultrasound exposure in the dorsal striatum. *Brain Stimulation*, 16(4),
1016 1196-1204.
- 1017 Liu, L., Du, J., Zheng, T., Hu, S., Dong, Y., Du, D., Wu, S., Wang, X., & Shi, Q. (2019). Protective effect
1018 of low-intensity transcranial ultrasound stimulation after differing delay following an acute
1019 ischemic stroke. *Brain Research Bulletin*, 146, 22-27.
- 1020 Macefield, V. G., & Henderson, L. A. (2020). Identifying increases in activity of the human RVLM through
1021 MSNA-coupled fMRI. *Frontiers in Neuroscience*, 13, 496481.
- 1022 Magara, A., Bühler, R., Moser, D., Kowalski, M., Pourtehrani, P., & Jeanmonod, D. (2014). First
1023 experience with MR-guided focused ultrasound in the treatment of Parkinson's disease. *Journal of
1024 therapeutic ultrasound*, 2(1).
- 1025 Mandonnet, E., Sarubbo, S., & Duffau, H. (2017). Proposal of an optimized strategy for intraoperative
1026 testing of speech and language during awake mapping. *Neurosurgical Review*, 40(1), 29-35.

- 1027 Manuel, T. J., Kusunose, J., Zhan, X., Lv, X., Kang, E., Yang, A., Xiang, Z., & Caskey, C. F. (2020).
1028 Ultrasound neuromodulation depends on pulse repetition frequency and can modulate inhibitory
1029 effects of TTX. *Scientific reports*, *10*(1), 15347.
- 1030 Martin, E., Aubry, J.-F., Schafer, M., Verhagen, L., Treeby, B., & Pauly, K. B. (2024). ITRUSST consensus
1031 on standardised reporting for transcranial ultrasound stimulation. *Brain Stimulation*.
- 1032 Mathias, R. N., De Aguiar, P. H. P., Da Luz Oliveira, E. P., Verst, S. M., Vieira, V., Docema, M. F., &
1033 Maldaun, M. V. C. (2016). “Next Door” intraoperative magnetic resonance imaging for awake
1034 craniotomy: Preliminary experience and technical note. *Surgical Neurology International*, *7*(Suppl
1035 40), S1021-S1021.
- 1036 Mehta, R. I., Carpenter, J. S., Mehta, R. I., Haut, M. W., Ranjan, M., Najib, U., Lockman, P., Wang, P.,
1037 D’Haese, P. F., & Rezai, A. R. (2021). Blood-brain barrier opening with MRI-guided focused
1038 ultrasound elicits meningeal venous permeability in humans with early Alzheimer disease.
1039 *Radiology*, *298*(3), 654-662.
- 1040 Meng, Y., Solomon, B., Boutet, A., Llinas, M., Scantlebury, N., Huang, Y., Hynynen, K., Hamani, C.,
1041 Fasano, A., Lozano, A. M., Lipsman, N., & Schwartz, M. L. (2018). Magnetic resonance-guided
1042 focused ultrasound thalamotomy for treatment of essential tremor: A 2-year outcome study.
1043 *Movement Disorders*, *33*(10), 1647-1650.
- 1044 Mihran, R. T., Barnes, F. S., & Wachtel, H. (1990). Temporally-specific modification of myelinated axon
1045 excitability in vitro following a single ultrasound pulse. *Ultrasound in medicine & biology*, *16*(3),
1046 297-309.
- 1047 Monti, M. M., Schnakers, C., Korb, A. S., Bystritsky, A., & Vespa, P. M. (2016). Non-Invasive Ultrasonic
1048 Thalamic Stimulation in Disorders of Consciousness after Severe Brain Injury: A First-in-Man
1049 Report. *Brain Stimulation*, *9*(6), 940-941.
- 1050 Moser, D., Zadicario, E., Schiff, G., & Jeanmonod, D. (2013). MR-guided focused ultrasound technique in
1051 functional neurosurgery: targeting accuracy. *Journal of therapeutic ultrasound*, *1*(1), 3-3.
- 1052 Mueller, J., Legon, W., Opitz, A., Sato, T. F., & Tyler, W. J. (2014). Transcranial focused ultrasound
1053 modulates intrinsic and evoked EEG dynamics. *Brain Stimulation*, *7*(6), 900-908.
- 1054 Mukherjee, A., & Halassa, M. M. (2024). The associative thalamus: a switchboard for cortical operations
1055 and a promising target for schizophrenia. *The Neuroscientist*, *30*(1), 132-147.
- 1056 Munoz, F., Meaney, A., Gross, A., Liu, K., Pouliopoulos, A., Liu, D., Konofagou, E., & Ferrera, V. (2022).
1057 Long term study of motivational and cognitive effects of low-intensity focused ultrasound
1058 neuromodulation in the dorsal striatum of nonhuman primates. *Brain Stimulation*, *15*(2), 360-372.
- 1059 Nashef, L., & Brown, S. (1996). Epilepsy and sudden death. *The Lancet*, *348*(9038), 1324-1325.
- 1060 Nicodemus, N. E., Becerra, S., Kuhn, T. P., Packham, H. R., Duncan, J., Mahdavi, K., Iovine, J., Kesari,
1061 S., Pereles, S., Whitney, M., Mamoun, M., Franc, D., Bystritsky, A., & Jordan, S. (2019). Focused
1062 transcranial ultrasound for treatment of neurodegenerative dementia. *Alzheimer's & Dementia :
1063 Translational Research & Clinical Interventions*, *5*, 374-374.
- 1064 Nobis, W. P., Otárola, K. A. G., Templer, J. W., Gerard, E. E., VanHaerents, S., Lane, G., Zhou, G.,
1065 Rosenow, J. M., Zelano, C., & Schuele, S. (2019). The effect of seizure spread to the amygdala on
1066 respiration and onset of ictal central apnea. *Journal of neurosurgery*, *132*(5), 1313-1323.
- 1067 Oghli, Y. S., Grippe, T., Arora, T., Hoque, T., Darmani, G., & Chen, R. (2023). Mechanisms of theta burst
1068 transcranial ultrasound induced plasticity in the human motor cortex. *Brain Stimulation*, *16*(4),
1069 1135-1143.

- 1070 Oh, S.-J., Lee, J. M., Kim, H.-B., Lee, J., Han, S., Bae, J. Y., Hong, G.-S., Koh, W., Kwon, J., & Hwang,
1071 E.-S. (2019). Ultrasonic neuromodulation via astrocytic TRPA1. *Current Biology*, 29(20), 3386-
1072 3401. e3388.
- 1073 Ozenne, V., Constans, C., Bour, P., Santin, M. D., Valabrègue, R., Ahnine, H., Pouget, P., Lehericy, S.,
1074 Aubry, J.-F., & Quesson, B. (2020). MRI monitoring of temperature and displacement for
1075 transcranial focus ultrasound applications. *NeuroImage*, 204, 116236.
- 1076 Pasquinelli, C., Hanson, L. G., Siebner, H. R., Lee, H. J., & Thielscher, A. (2019). Safety of transcranial
1077 focused ultrasound stimulation: A systematic review of the state of knowledge from both human
1078 and animal studies. *Brain Stimulation*, 12(6), 1367-1380.
- 1079 Petersen, E. N., Chung, H.-W., Nayebosadri, A., & Hansen, S. B. (2016). Kinetic disruption of lipid rafts
1080 is a mechanosensor for phospholipase D. *Nature communications*, 7(1), 13873.
- 1081 Plaksin, M., Kimmel, E., & Shoham, S. (2016). Cell-Type-Selective Effects of Intramembrane Cavitation
1082 as a Unifying Theoretical Framework for Ultrasonic Neuromodulation. *eNeuro*, 3(3), 229-244.
- 1083 Plaksin, M., Shoham, S., & Kimmel, E. (2014). Intramembrane cavitation as a predictive bio-piezoelectric
1084 mechanism for ultrasonic brain stimulation. *Physical review X*, 4(1), 011004.
- 1085 Ren, L., Zhai, Z., Xiang, Q., Zhuo, K., Zhang, S., Zhang, Y., Jiao, X., Tong, S., Liu, D., & Sun, J. (2023).
1086 Transcranial ultrasound stimulation modulates the interhemispheric balance of excitability in
1087 human motor cortex. *Journal of neural engineering*, 20(1), 016043.
- 1088 Rezai, A. R., Ranjan, M., D'Haese, P. F., Haut, M. W., Carpenter, J., Najib, U., Mehta, R. I., Chazen, J. L.,
1089 Zibly, Z., Yates, J. R., Hodder, S. L., & Kaplitt, M. (2020). Noninvasive hippocampal blood-brain
1090 barrier opening in Alzheimer's disease with focused ultrasound. *Proceedings of the National
1091 Academy of Sciences of the United States of America*, 117(17), 9180-9182.
- 1092 Reznik, S. J., Sanguinetti, J. L., Tyler, W. J., Daft, C., & Allen, J. J. B. (2020). A double-blind pilot study
1093 of transcranial ultrasound (TUS) as a five-day intervention: TUS mitigates worry among depressed
1094 participants. *Neurology Psychiatry and Brain Research*, 37, 60-66.
- 1095 Rhone, A. E., Kovach, C. K., Harmata, G. I., Sullivan, A. W., Tranel, D., Ciliberto, M. A., Howard, M. A.,
1096 Richerson, G. B., Steinschneider, M., & Wemmie, J. A. (2020). A human amygdala site that inhibits
1097 respiration and elicits apnea in pediatric epilepsy. *JCI insight*, 5(6).
- 1098 Rohani, M., & Fasano, A. (2017). Focused ultrasound for essential tremor: review of the evidence and
1099 discussion of current hurdles. *Tremor and Other Hyperkinetic Movements*, 7.
- 1100 Roumazeilles, L., Schurz, M., Lojkiewicz, M., Verhagen, L., Schüffelgen, U., Marche, K., Mahmoodi, A.,
1101 Emberton, A., Simpson, K., & Joly, O. (2021). Social prediction modulates activity of macaque
1102 superior temporal cortex. *Science advances*, 7(38), eabh2392.
- 1103 Ryvlin, P., Nashef, L., Lhatoo, S. D., Bateman, L. M., Bird, J., Bleasel, A., Boon, P., Crespel, A.,
1104 Dworetzky, B. A., & Høgenhaven, H. (2013). Incidence and mechanisms of cardiorespiratory
1105 arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. *The Lancet Neurology*,
1106 12(10), 966-977.
- 1107 Samuel, N., Ding, M. Y. R., Sarica, C., Darmani, G., Harmsen, I. E., Grippe, T., Chen, X., Yang, A.,
1108 Nasrkhani, N., Zeng, K., Chen, R., & Lozano, A. M. (2023). Accelerated Transcranial Ultrasound
1109 Neuromodulation in Parkinson's Disease: A Pilot Study. *Movement Disorders*.
- 1110 Samuel, N., Zeng, K., Harmsen, I. E., Ding, M. Y. R., Darmani, G., Sarica, C., Santyr, B., Vetkas, A.,
1111 Pancholi, A., Fomenko, A., Milano, V., Yamamoto, K., Saha, U., Wennberg, R., Rowland, N. C.,

- 1112 Chen, R., & Lozano, A. M. (2022). Multi-modal investigation of transcranial ultrasound-induced
1113 neuroplasticity of the human motor cortex. *15*(6), 1337-1347.
- 1114 Sanguinetti, J. L., Hameroff, S., Smith, E. E., Sato, T., Daft, C. M. W., Tyler, W. J., & Allen, J. J. B. (2020).
1115 Transcranial Focused Ultrasound to the Right Prefrontal Cortex Improves Mood and Alters
1116 Functional Connectivity in Humans. *Frontiers in Human Neuroscience*, *14*, 494085-494085.
- 1117 Schellinger, P. D., Alexandrov, A. V., Barreto, A. D., Demchuk, A. M., Tsivgoulis, G., Kohrmann, M.,
1118 Alleman, J., Howard, V., Howard, G., Alexandrov, A. W., Brandt, G., & Molina, C. A. (2015).
1119 Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator for
1120 Emergent Revascularization in Acute Ischemic Stroke (Clotbust-ER): Design and Methodology of
1121 a Multinational Phase 3 Trial. <https://doi.org/10.1111/ijvs.12536>, *10*(7), 1141-1148.
- 1122 Schimek, N., Burke-Conte, Z., Abernethy, J., Schimek, M., Burke-Conte, C., Bobola, M., Stocco, A., &
1123 Mourad, P. D. (2020). Repeated application of transcranial diagnostic ultrasound towards the visual
1124 cortex induced illusory visual percepts in healthy participants. *Frontiers in Human Neuroscience*,
1125 *14*, 66.
- 1126 Shimokawa, H., Shindo, T., Ishiki, A., Tomita, N., Ichijyo, S., Watanabe, T., Nakata, T., Eguchi, K.,
1127 Kikuchi, Y., & Shiroto, T. (2022). A pilot study of whole-brain low-intensity pulsed ultrasound
1128 therapy for early stage of Alzheimer's disease (LIPUS-AD): A randomized, double-blind, placebo-
1129 controlled trial. *The Tohoku Journal of Experimental Medicine*, *258*(3), 167-175.
- 1130 Shoemaker, J. K. (2022). Forebrain network associated with cardiovascular control in exercising humans.
1131 *Exercise and Sport Sciences Reviews*, *50*(4), 175-184.
- 1132 Solomon, E., Wang, J., Oya, H., Howard, M., Trapp, N., Uitermarkt, B., Boes, A., & Keller, C. (2024). 4.
1133 TMS Provokes Target-Dependent Intracranial Rhythms Across Human Cortical and Subcortical
1134 Sites. *Biological Psychiatry*, *95*(10), S75.
- 1135 Spivak, N. M., Korb, A. S., Reyes, S. D., Bych, B. P., Schafer, S. F., Khanlou, N., Johnson, E. A., Schafer,
1136 M. E., Cohen, M. S., & Kuhn, T. (2021). Histological examination of focused ultrasound effects
1137 on human brain tissue. *Brain Stimulation*, *14*(6), 1486-1488.
- 1138 Spivak, N. M., Sanguinetti, J. L., & Monti, M. M. (2022). Focusing in on the Future of Focused Ultrasound
1139 as a Translational Tool. *Brain Sciences 2022, Vol. 12, Page 158*, *12*(2), 158-158.
- 1140 Su, W.-S., Wu, C.-H., Chen, S.-F., & Yang, F.-Y. (2017). Transcranial ultrasound stimulation promotes
1141 brain-derived neurotrophic factor and reduces apoptosis in a mouse model of traumatic brain injury.
1142 *Brain Stimulation*, *10*(6), 1032-1041.
- 1143 Suki, B., Parameswaran, H., Alves, C., Araújo, A. D., & Bartolák-Suki, E. (2020). Cellular and
1144 Extracellular Homeostasis in Fluctuating Mechanical Environments. *Studies in Mechanobiology*,
1145 *Tissue Engineering and Biomaterials*, *23*, 83-121.
- 1146 Tarapore, P. E., Findlay, A. M., Honma, S. M., Mizuiri, D., Houde, J. F., Berger, M. S., & Nagarajan, S. S.
1147 (2013). Language mapping with navigated repetitive TMS: proof of technique and validation.
1148 *NeuroImage*, *82*, 260-272.
- 1149 Thorpe, R. V., Black, C. J., Borton, D. A., Hu, L., Saab, C. Y., & Jones, S. R. (2024). Distinct neocortical
1150 mechanisms underlie human SI responses to median nerve and laser evoked peripheral activation.
1151 *Imaging Neuroscience*.
- 1152 Thurman, D. J., Hesdorffer, D. C., & French, J. A. (2014). Sudden unexpected death in epilepsy: assessing
1153 the public health burden. *Epilepsia*, *55*(10), 1479-1485.

- 1154 Trapp, N. T., Bruss, J. E., Manzel, K., Grafman, J., Tranel, D., & Boes, A. D. (2023). Large-scale lesion
1155 symptom mapping of depression identifies brain regions for risk and resilience. *Brain*, *146*(4),
1156 1672-1685.
- 1157 Treeby, B. E., & Cox, B. T. (2010). k-Wave: MATLAB toolbox for the simulation and reconstruction of
1158 photoacoustic wave fields. *Journal of biomedical optics*, *15*(2), 021314-021314-021312.
- 1159 Tsui, P. H., Wang, S. H., & Huang, C. C. (2005). In vitro effects of ultrasound with different energies on
1160 the conduction properties of neural tissue. *Ultrasonics*, *43*(7), 560-565.
- 1161 Tufail, Y., Matyushov, A., Baldwin, N., Tauchmann, M. L., Georges, J., Yoshihiro, A., Tillery, S. I. H., &
1162 Tyler, W. J. (2010). Transcranial pulsed ultrasound stimulates intact brain circuits. *Neuron*, *66*(5),
1163 681-694.
- 1164 Tyler, W. J. (2011). Noninvasive neuromodulation with ultrasound? A continuum mechanics hypothesis.
1165 *The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry*, *17*(1), 25-
1166 36.
- 1167 Verhagen, L., Gallea, C., Folloni, D., Constans, C., Jensen, D. E. A., Ahnine, H., Roumazeilles, L., Santin,
1168 M., Ahmed, B., Lehericy, S., Klein-Flügge, M. C., Krug, K., Mars, R. B., Rushworth, M. F. S.,
1169 Pouget, P., Aubry, J. F., & Sallet, J. (2019). Offline impact of transcranial focused ultrasound on
1170 cortical activation in primates. *eLife*, *8*.
- 1171 Wang, Y., Li, F., He, M.-J., & Chen, S.-J. (2022). The effects and mechanisms of transcranial ultrasound
1172 stimulation combined with cognitive rehabilitation on post-stroke cognitive impairment.
1173 *Neurological Sciences*, *43*(7), 4315-4321.
- 1174 Wu, C.-T., Yang, T.-H., Chen, M.-C., Chung, Y.-P., Guan, S.-S., Long, L.-H., Liu, S.-H., & Chen, C.-M.
1175 (2019). Low intensity pulsed ultrasound prevents recurrent ischemic stroke in a cerebral
1176 ischemia/reperfusion injury mouse model via brain-derived neurotrophic factor induction.
1177 *International Journal of Molecular Sciences*, *20*(20), 5169.
- 1178 Xia, X., Fomenko, A., Nankoo, J.-F., Zeng, K., Wang, Y., Zhang, J., Lozano, A. M., & Chen, R. (2021).
1179 Time course of the effects of low-intensity transcranial ultrasound on the excitability of ipsilateral
1180 and contralateral human primary motor cortex. *NeuroImage*, *243*, 118557.
- 1181 Yang, F.-Y., Lu, W.-W., Lin, W.-T., Chang, C.-W., & Huang, S.-L. (2015). Enhancement of neurotrophic
1182 factors in astrocyte for neuroprotective effects in brain disorders using low-intensity pulsed
1183 ultrasound stimulation. *Brain Stimulation*, *8*(3), 465-473.
- 1184 Yoo, S., Mittelstein, D. R., Hurt, R. C., Lacroix, J., & Shapiro, M. G. (2022). Focused ultrasound excites
1185 cortical neurons via mechanosensitive calcium accumulation and ion channel amplification. *13*(1),
1186 1-13.
- 1187 Yoo, S. S., Bystritsky, A., Lee, J. H., Zhang, Y., Fischer, K., Min, B. K., McDannold, N. J., Pascual-Leone,
1188 A., & Jolesz, F. A. (2011). Focused ultrasound modulates region-specific brain activity.
1189 *NeuroImage*, *56*(3), 1267-1275.
- 1190 Younan, Y., Deffieux, T., Larrat, B., Fink, M., Tanter, M., & Aubry, J. F. (2013). Influence of the pressure
1191 field distribution in transcranial ultrasonic neurostimulation. *Medical physics*, *40*(8).
- 1192 Yu, K., Liu, C., Niu, X., & He, B. (2020). Transcranial focused ultrasound neuromodulation of voluntary
1193 movement-related cortical activity in humans. *IEEE Transactions on Biomedical Engineering*,
1194 *68*(6), 1923-1931.

- 1195 Yu, K., Liu, C., Niu, X., & He, B. (2020a). Transcranial focused ultrasound neuromodulation of voluntary
1196 movement-related cortical activity in humans. *IEEE Transactions on Biomedical Engineering*,
1197 68(6), 1923-1931.
- 1198 Zeng, K., Darmani, G., Fomenko, A., Xia, X., Tran, S., Nankoo, J. F., Shamli Oghli, Y., Wang, Y., Lozano,
1199 A. M., & Chen, R. (2022). Induction of Human Motor Cortex Plasticity by Theta Burst Transcranial
1200 Ultrasound Stimulation. *Annals of Neurology*, 91(2), 238-252.
- 1201 Zhai, Z., Ren, L., Song, Z., Xiang, Q., Zhuo, K., Zhang, S., Li, X., Zhang, Y., Jiao, X., & Tong, S. (2023).
1202 The efficacy of low-intensity transcranial ultrasound stimulation on negative symptoms in
1203 schizophrenia: a double-blind, randomized sham-controlled study. *Brain Stimulation: Basic,*
1204 *Translational, and Clinical Research in Neuromodulation*, 16(3), 790-792.
- 1205 Zhang, M.-F., Chen, W.-Z., Huang, F.-B., Peng, Z.-Y., Quan, Y.-C., & Tang, Z.-M. (2022). Low-intensity
1206 transcranial ultrasound stimulation facilitates hand motor function and cortical excitability: A
1207 crossover, randomized, double blind study. *Frontiers in neurology*, 13, 926027.
- 1208 Zhang, T., Guo, B., Zuo, Z., Long, X., Hu, S., Li, S., Su, X., Wang, Y., & Liu, C. (2023). Excitatory-
1209 inhibitory modulation of transcranial focus ultrasound stimulation on human motor cortex. *CNS*
1210 *Neuroscience & Therapeutics*, 29(12), 3829-3841.
- 1211 Zhang, T., Pan, N., Wang, Y., Liu, C., & Hu, S. (2021). Transcranial Focused Ultrasound Neuromodulation:
1212 A Review of the Excitatory and Inhibitory Effects on Brain Activity in Human and Animals.
1213 *Frontiers in Human Neuroscience*, 15, 749162-749162.
- 1214 Zhang, Y., Ren, L., Liu, K., Tong, S., Yuan, T.-F., & Sun, J. (2021). Transcranial ultrasound stimulation of
1215 the human motor cortex. *Iscience*, 24(12).
- 1216 Zhou, Y.-F. (2011). High intensity focused ultrasound in clinical tumor ablation. *World journal of clinical*
1217 *oncology*, 2(1), 8-8.
- 1218